var title_f8_9_8336="Progressive fibrosis CXR";
var content_f8_9_8336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Progressive massive fibrosis (PMF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with end-stage silicosis complicated by respiratory failure. There is upward retraction of hila, and the lower zones are hyperinflated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. J. Parker.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8336=[""].join("\n");
var outline_f8_9_8336=null;
var title_f8_9_8337="Diethylamine salicylate: International drug information";
var content_f8_9_8337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diethylamine salicylate: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aciphen (HU);",
"     </li>",
"     <li>",
"      Algesal (BE, IT, NO);",
"     </li>",
"     <li>",
"      Algesal[+Myrtecaine] (AT, CH, CZ, DE, ES, FI, GB, HU, NL, SE);",
"     </li>",
"     <li>",
"      Algiderma (PT);",
"     </li>",
"     <li>",
"      Algoderm (ES);",
"     </li>",
"     <li>",
"      Algoflex (IT);",
"     </li>",
"     <li>",
"      Artrogota (ES);",
"     </li>",
"     <li>",
"      Gallisal (FI);",
"     </li>",
"     <li>",
"      Multigesic (IN);",
"     </li>",
"     <li>",
"      Rheumagel-Dr. Schmidgall (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of rheumatic and muscular pain",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply 2-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: 1%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10366 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-1.234.2.38-35693F307E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8337=[""].join("\n");
var outline_f8_9_8337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303301\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978504\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978507\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978503\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821236\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978506\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10366|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_9_8338="PMLE hand";
var content_f8_9_8338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules developed on the dorsal hands, forearms, face, neck, and upper chest of this 40-year-old man with a history of sun exposure. The patient's history and symptoms were consistent with polymorphous light eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8338=[""].join("\n");
var outline_f8_9_8338=null;
var title_f8_9_8339="Follicular lymphoma in adults";
var content_f8_9_8339=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Follicular lymphoma in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/9/8339/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8339/contributors\" id=\"au4525\">",
"       Arnold S Freedman, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8339/contributors\" id=\"au5177\">",
"       Jonathan W Friedberg, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/9/8339/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8339/contributors\" id=\"se6587\">",
"       Andrew Lister, MD, FRCP, FRCPath, FRCR",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/9/8339/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8339/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?8/9/8339?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      FOLLICULAR LYMPHOMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Lymphoma is a cancer of lymphocytes, a type of white blood cell. Lymphocytes circulate in the body through a network referred to as the lymphatic system, which includes the bone marrow, spleen, thymus, and lymph nodes. The organs and vessels of the lymphatic system work together to produce and store cells that fight infection (",
"     <a class=\"graphic graphic_figure graphicRef64350 \" href=\"UTD.htm?23/55/24439\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     There are two main types of lymphoma:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Hodgkin lymphoma (HL)",
"      </li>",
"      <li>",
"       Non-Hodgkin lymphoma (NHL)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Non-Hodgkin lymphoma (NHL) is the most common type of lymphoma. Follicular lymphoma is one form of NHL. In contrast to some of the other forms of NHL, follicular lymphoma usually grows slowly and thus may not require treatment for many years.",
"    </p>",
"    <p>",
"     The following discussion will review the risk factors, classification, symptoms, and treatment of follicular lymphoma.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      FOLLICULAR LYMPHOMA RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Age, gender, and ethnicity affect a person's likelihood of developing follicular lymphoma. Follicular lymphoma is slightly more likely to be diagnosed in women than men, and is less common among Asians and Blacks than among people of other ethnicities. Nearly everyone diagnosed with follicular lymphoma is an adult, with the average age at diagnosis being 60 years.",
"    </p>",
"    <p>",
"     Follicular lymphoma is not an inherited disease. Siblings and children of patients with follicular lymphoma do not have a substantially increased risk of developing follicular lymphoma.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      FOLLICULAR LYMPHOMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The initial symptoms of follicular lymphoma include painless swelling in one or more lymph nodes, particularly in the neck, armpit, or groin areas. Often, people with follicular lymphoma complain that their lymph nodes have been swollen for a long time; the size may increase and decrease several times before they seek medical attention.",
"    </p>",
"    <p>",
"     Some people with follicular lymphoma develop large tumors in the abdomen. These may cause no symptoms, but can block normal flow in the digestive or urinary system or in a blood vessel.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      FOLLICULAR LYMPHOMA DIAGNOSIS AND STAGING",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of follicular lymphoma is confirmed by removing all or part of an enlarged lymph node to examine its cells under a microscope, a procedure known as a biopsy.",
"    </p>",
"    <p>",
"     Once the diagnosis is confirmed, additional tests are performed to obtain more information about the extent to which the disease has spread in the body. This process is called staging. The results of these tests will help determine the most effective course of treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      History and physical exam",
"     </span>",
"     &nbsp;&mdash;&nbsp;A careful interview and physical examination will help determine the extent of the disease. The physical exam may reveal swollen lymph nodes in various locations (",
"     <a class=\"graphic graphic_figure graphicRef64350 \" href=\"UTD.htm?23/55/24439\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Staging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of tests are available to help determine which areas of the body have been affected by follicular lymphoma. Tests that may be done include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Blood tests",
"      </li>",
"      <li>",
"       Bone marrow biopsy (removal of a small sample of tissue from the bone marrow, the spongy area in the middle of large bones, for analysis)",
"      </li>",
"      <li>",
"       CT scan",
"      </li>",
"      <li>",
"       PET scan",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Staging terms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following are terms used in the staging criteria:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lymph node regions: An area of lymph nodes and the surrounding tissue. Examples include the cervical nodes in the neck (",
"       <a class=\"graphic graphic_figure graphicRef55189 \" href=\"UTD.htm?24/8/24709\">",
"        figure 2",
"       </a>",
"       ), the axillary nodes in the armpit, the inguinal nodes in the groin, or the mediastinal nodes in the chest (",
"       <a class=\"graphic graphic_figure graphicRef67527 \" href=\"UTD.htm?40/17/41237\">",
"        figure 3",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Lymph structures: Organs or structures that are part of the lymphatic system, such as the lymph nodes, spleen, and thymus gland.",
"      </li>",
"      <li>",
"       Diaphragm: A large muscle that separates the chest cavity from the abdominal cavity.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Stage grouping",
"     </span>",
"     &nbsp;&mdash;&nbsp;Staging involves dividing patients into groups (stages) based upon how much of the lymphatic system is involved at the time of diagnosis. Staging helps determine a person's prognosis and whether treatment is required (",
"     <a class=\"graphic graphic_table graphicRef66845 \" href=\"UTD.htm?12/36/12875\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The stages of lymphoma are defined as follows:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stage I &mdash; Only one lymph node region is involved, or only one lymph structure is involved.",
"      </li>",
"      <li>",
"       Stage II &mdash; Two or more lymph node regions or lymph node structures on the same side of the diaphragm are involved.",
"      </li>",
"      <li>",
"       Stage III &mdash; Lymph node regions or structures on both sides of the diaphragm are involved.",
"      </li>",
"      <li>",
"       Stage IV &mdash; There is widespread involvement of a number of organs or tissues other than lymph node regions or structures, such as the bone marrow.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When a stage is assigned, it also includes a letter, A or B, to denote whether fever, weight loss, or night sweats are present. \"A\" means these symptoms are not present; \"B\" means they are. For example, a person with stage 1B disease has evidence of cancer in one lymph node region and has \"B\" symptoms (fever, weight loss, or night sweats). (See",
"     <a class=\"local\" href=\"#H3\">",
"      'Follicular lymphoma symptoms'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      FOLLICULAR LYMPHOMA DISEASE PROGRESSION",
"     </span>",
"    </p>",
"    <p>",
"     The progression of follicular lymphoma varies from one person to another, depending upon the speed of the tumor's growth and the involvement of other organs. Sometimes, people with follicular lymphoma have no symptoms for many years and do not need treatment. In other people, treatment may be required for symptoms. Examples of symptoms that may lead to treatment include fever, night sweats, weight loss, pain, blockage of organs, and anemia or other changes in blood counts.",
"    </p>",
"    <p>",
"     Some cases of follicular lymphoma either behave like or transform into a more aggressive form of lymphoma, such as diffuse large B-cell lymphoma, which grows more rapidly and requires more intensive treatment. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"      \"Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      FOLLICULAR LYMPHOMA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment for follicular lymphoma depends on the person's symptoms, tumor grade, age, and general health. The majority of people with follicular lymphoma have widespread disease when first diagnosed. However, because follicular lymphoma is slow growing, it may take many years for the disease to progress, during which time treatment may not be needed. Early treatment does not always improve overall survival if a person has no symptoms and the disease is not affecting their organs. Thus, close observation (a \"watch and wait\" approach) is often recommended.",
"    </p>",
"    <p>",
"     Furthermore, the slow-growth characteristics make the tumors relatively less responsive to standard forms of cancer treatment (compared with the more aggressive lymphomas). As a result, a cure is not usually possible; the main reason to treat is to improve symptoms.",
"    </p>",
"    <p>",
"     Features that may warrant treatment include one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Progressively enlarging lymph nodes",
"      </li>",
"      <li>",
"       Fever, weight loss, or night sweats",
"      </li>",
"      <li>",
"       Low blood counts",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     People without these features are usually monitored with periodic physical examination and blood testing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Early-stage disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some patients with early-stage follicular lymphoma (stage I or II) who develop symptoms may be treated with radiation therapy alone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy uses high-energy beams to slow or stop the growth of cancer cells and is administered to the region of affected lymph nodes (called involved field radiation) or to the affected and surrounding lymph nodes (called extended-field radiation). Radiation therapy must be given in small daily doses over a period of weeks to minimize the side effects; the number of weeks depends upon the amount of radiation to be administered.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Advanced-stage disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Advanced-stage disease includes stage III and IV follicular lymphoma. Some patients with stage II disease will be treated as though they have advanced-stage disease.",
"    </p>",
"    <p>",
"     There are many treatment options for patients with advanced-stage disease. The choice of treatment depends upon the patient's preference and the need for the treatment to act quickly (if organ function is threatened by the follicular lymphoma). Most advanced-stage follicular lymphoma is treated with rituximab (Rituxan&reg;) plus chemotherapy. For older people who have symptoms but have no evidence of organ blockage, monoclonal antibody therapy with rituximab (Rituxan&reg;) may be recommended (see",
"     <a class=\"local\" href=\"#H14\">",
"      'Monoclonal antibody treatment'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Patients with follicular lymphoma that decreases in size after being treated with rituximab may choose to receive further treatments with rituximab as &ldquo;maintenance therapy.&rdquo; Maintenance therapy postpones progression of the lymphoma. It is not yet clear whether maintenance therapy improves survival.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Monoclonal antibody treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rituximab (Rituxan&reg;) is a monoclonal antibody used to treat follicular lymphoma. Rituximab is frequently combined with chemotherapy treatments.",
"    </p>",
"    <p>",
"     A monoclonal antibody is a purified protein that targets a specific group of cells (usually cancer cells). This has advantages over other cancer treatments such as chemotherapy, which targets all rapidly growing cells. There are usually fewer side effects and long-term risks of monoclonal antibody therapies as compared with traditional chemotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy refers to the use of medicines to stop or slow the growth of cancer cells. Chemotherapy works by interfering with the ability of rapidly growing cells (like cancer cells) to divide or multiply. Because most of an adult's normal cells are not actively dividing or multiplying, they are not affected by chemotherapy. However, the bone marrow (where the blood cells are produced), the hair follicles, and the lining of the gastrointestinal (GI) tract are all growing. The side effects of chemotherapy drugs are related to effects on these and other normal tissues.",
"    </p>",
"    <p>",
"     A chemotherapy drug or combination of drugs is referred to as a regimen. Regimens used for the treatment of follicular lymphoma may include a single agent taken by mouth on a daily basis, while other regimens are given intravenously in cycles. A cycle of chemotherapy refers to the time it takes to give the drugs and the time required for the body to recover. For example, a typical chemotherapy regimen is a one-hour IV infusion of two or more different chemotherapy medications given once every three to four weeks. This three- or four-week period is one cycle of therapy. If this regimen were repeated for a total of three or four cycles, it would take up to four months to complete.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Radioimmunotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radioimmunotherapy (RIT) uses radioactive isotopes that are linked to monoclonal antibodies. As a result, radiation therapy can be delivered directly to proteins on cancer cells, which reduces the amount of radiation delivered to healthy tissues. The radioimmunotherapy treatments used for follicular lymphoma include 90 Y-ibritumomab tiuxetan (Zevalin&reg;) or 131I-tositumomab (Bexxar&reg;), both of which are given through a vein. The person is usually given treatment in a hospital-based setting but may go home after treatment is completed.",
"    </p>",
"    <p>",
"     Administering RIT requires specialized equipment and additional training of physicians, nurses, and other involved personnel. The cost of RIT is quite high, and there are potentially serious short- and long-term side effects of the treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Bone marrow transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hematopoietic stem cell (bone marrow) transplantation is generally reserved for people whose lymphoma has recurred after treatment. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Clinical trials",
"     </span>",
"     &nbsp;&mdash;&nbsp;A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Clinical trials are especially important for persons with follicular lymphoma since there is no treatment currently available to cure this disease. Ask a healthcare provider for more information, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      FOLLICULAR LYMPHOMA PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     For patients with advanced forms of follicular lymphoma (ie, stages III and IV disease) (",
"     <a class=\"graphic graphic_table graphicRef66845 \" href=\"UTD.htm?12/36/12875\">",
"      table 1",
"     </a>",
"     ), the average survival is more than 10 years. Despite its slow-growing nature, most cases of follicular lymphoma are not curable with currently available therapies.",
"    </p>",
"    <p>",
"     Researchers have developed a way to estimate how long a person with lymphoma is likely to live based on what they call \"The Follicular Lymphoma International Prognostic Index\" (FLIPI). This index takes into account five factors that affect prognosis. The index can also help doctors identify which patients will benefit from specific chemotherapy treatments.",
"    </p>",
"    <p>",
"     The five factors involved in the FLIPI are:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Age older than 60 years",
"      </li>",
"      <li>",
"       Stage III or IV disease (",
"       <a class=\"graphic graphic_table graphicRef66845 \" href=\"UTD.htm?12/36/12875\">",
"        table 1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Low red blood cell count",
"      </li>",
"      <li>",
"       More than four involved lymph node areas (",
"       <a class=\"graphic graphic_figure graphicRef64350 \" href=\"UTD.htm?23/55/24439\">",
"        figure 1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Lactate dehydrogenase level higher than normal (lactate dehydrogenase is a protein found in blood whose levels increase when tissues have been damaged)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     On average, the more of these risk factors a person has, the worse his or her prognosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287395727\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H252329\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=see_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/23/18802?source=see_link\">",
"      Patient information: Follicular lymphoma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H252344\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link\">",
"      Hematopoietic cell transplantation in follicular lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Leukemia &amp; Lymphoma Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.leukemia-lymphoma.org/\">",
"      www.leukemia-lymphoma.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?8/9/8339/abstract/1\">",
"      1",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?8/9/8339?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     American Cancer Society. What is non-Hodgkin's lymphoma? www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_Is_Non_Hodgkins_Lymphoma_32.asp (Accessed on September 13, 2011).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f8_9_8339=[""].join("\n");
var outline_f8_9_8339=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           FOLLICULAR LYMPHOMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           FOLLICULAR LYMPHOMA RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           FOLLICULAR LYMPHOMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           FOLLICULAR LYMPHOMA DIAGNOSIS AND STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           FOLLICULAR LYMPHOMA DISEASE PROGRESSION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           FOLLICULAR LYMPHOMA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           FOLLICULAR LYMPHOMA PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/55/24439\" title=\"figure 1\">",
"           Lymph nodes body PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/8/24709\" title=\"figure 2\">",
"           Lymph nodes head neck PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\" title=\"figure 3\">",
"           Normal lung anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?12/36/12875\" title=\"table 1\">",
"           Ann Arbor staging PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f8_9_8340="Mitral valve prolapse PI";
var content_f8_9_8340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Mitral valve prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mitral valve prolapse is a condition in which the mitral valve doesn&rsquo;t close normally. The mitral valve is made up of 2 flaps. In mitral valve prolapse, 1 or both flaps don&rsquo;t close in the correct way. When this happens, blood can leak backward in the wrong direction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8340=[""].join("\n");
var outline_f8_9_8340=null;
var title_f8_9_8341="EP study tracing showing VPB during atrial tachycardia mapping";
var content_f8_9_8341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Electrophysiologic (EP) study tracing showng a ventricular premature beat (VPB) during mapping of an atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high posterior right atrium (HRA); posterior left atrium (USER1 and USER 3); proximal, mid, and distal coronary sinus (CS9-10, CS5-6, CS1-2); and right ventricular apex (RVA) in a patient with atrial tachycardia. A ventricular premature beat (VPB) introduced from the right ventricular outflow tract has no effect on the underlying atrial tachycardia, but the onset of the P wave (P) in the surface ECG recordings can be seen more clearly as it is no longer superimposed on the T wave. The atrial electrogram (A) recorded from the right atrial catheter precedes the surface P wave by 30 msec, but the signal from the left atrial catheter (USER1) precedes the surface P wave by 50 msec (arrow).",
"    <div class=\"footnotes\">",
"     V: ventricular electrogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8341=[""].join("\n");
var outline_f8_9_8341=null;
var title_f8_9_8342="Esterified estrogen and methyltestosterone: Patient drug information";
var content_f8_9_8342=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Esterified estrogen and methyltestosterone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/25/14743?source=see_link\">",
"     see \"Esterified estrogen and methyltestosterone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Covaryx&reg;;",
"     </li>",
"     <li>",
"      Covaryx&reg; H.S.;",
"     </li>",
"     <li>",
"      EEMT&trade;;",
"     </li>",
"     <li>",
"      EEMT&trade; HS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens, when used in women after stopping periods (menopause), may raise the chance of uterine cancer. Progestins may lower this chance. A warning sign for cancer of the uterus is vaginal bleeding. Report any vaginal bleeding to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens to stop heart disease or dementia. Using estrogens may raise your chances of having a heart attack, a stroke, breast cancer, or a blood clot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens if you are pregnant. If you get pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702063",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estrogens (esterified), methyltestosterone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703394",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, liver disease, stroke, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, a deep voice, facial hair, pimples, or period changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11534 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8342=[""].join("\n");
var outline_f8_9_8342=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167642\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027308\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027310\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027309\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027314\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027315\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027317\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027312\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027313\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027318\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027319\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/25/14743?source=related_link\">",
"      Esterified estrogen and methyltestosterone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_9_8343="Acute complications during hemodialysis";
var content_f8_9_8343=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute complications during hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8343/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8343/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8343/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8343/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8343/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8343/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/9/8343/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute complications commonly occur during routine hemodialysis treatments. They include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypotension &mdash; 25 to 55 percent of treatments",
"     </li>",
"     <li>",
"      Cramps &mdash; 5 to 20 percent",
"     </li>",
"     <li>",
"      Nausea and vomiting &mdash; 5 to 15 percent",
"     </li>",
"     <li>",
"      Headache &mdash; 5 percent",
"     </li>",
"     <li>",
"      Chest pain &mdash; 2 to 5 percent",
"     </li>",
"     <li>",
"      Back pain &mdash; 2 to 5 percent",
"     </li>",
"     <li>",
"      Itching &mdash; 5 percent",
"     </li>",
"     <li>",
"      Fever and chills &mdash; Less than 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications are generally caused by multiple underlying mechanisms and are poorly understood. Knowledge of their pathogenesis is further complicated by their often simultaneous occurrence. As an example, hypotension with hemodialysis, which has a myriad of possible causes, may be accompanied by nausea, vomiting, headache,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest pain. Similarly, cramps may be associated with hypotension and are often very difficult to treat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36325?source=see_link\">",
"     \"Muscle cramps in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the causes, diagnosis, and treatment of nausea and vomiting, headache, chest pain and dyspnea in the nonhypotensive patient undergoing hemodialysis. Hemolysis, air embolism, and a brief overview of arrhythmias will also be presented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEADACHE, NAUSEA, AND VOMITING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longer treatment times",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrafiltration in association with a large degree of solute removal significantly enhance the incidence of headache, nausea, and vomiting during dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. It is important to emphasize that longer treatment times",
"    <strong>",
"     alone",
"    </strong>",
"    may not necessarily be associated with adverse effects. The lack of such effects with extended hemodialysis treatment times in the dialysis center in Taussin, France as well as with nocturnal hemodialysis indicate that length of treatment alone may be unimportant if the solute clearance rate is slow. In addition, dialyzer membrane composition (cellulosic versus noncellulosic), surface area, and biocompatibility are",
"    <strong>",
"     not",
"    </strong>",
"    significant factors underlying these intradialytic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since longer treatment times combined with high urea removal rates appear to be important, a variant of the dialysis disequilibrium syndrome may underlie these symptoms in many patients. Dialysis disequilibrium is thought to be due to water movement into the brain as a result of a reverse osmotic shift induced by urea removal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"     \"Dialysis disequilibrium syndrome\"",
"    </a>",
"    .) Although quite uncommon, the syndrome should be considered in the noncompliant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequately dialyzed patient who develops nausea, vomiting, or headache while being aggressively dialyzed. In this setting, initially altering the dialysis prescription in favor of less intensive and more frequent treatments may avoid these complications.",
"   </p>",
"   <p>",
"    Patients who have headaches on dialysis in the absence of hypotension and suspected dialysis disequilibrium should be questioned about caffeine use, which can sometimes precipitate headache [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, metabolic disturbances (eg, hypoglycemia, hypernatremia, and hyponatremia), uremia, subdural hematoma, and medication-induced headaches should be considered in patients with recurrent dialysis-associated headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"     \"Dialysis disequilibrium syndrome\"",
"    </a>",
"    .) Rarely, dialysis-associated headache may be associated with increased intra-ocular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, psychological factors may contribute to dialysis-associated somatic complaints. Using multiple logistic regression, one group found that a poor affect score on indices of affect and quality of life scales was the strongest correlate for predicting somatic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHEST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously discussed, chest pain that occurs while a patient is being dialyzed may be associated with hypotension or dialysis disequilibrium syndrome. Additional possibilities should always be considered; these include angina, hemolysis, and (rarely) air embolism. Furthermore, although pulmonary embolism is extremely uncommon in dialysis patients, this complication may be observed after manipulation of thrombus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occlusion of the dialysis access [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Acutely, the decision to continue or stop the dialysis treatment because of chest pain is based upon clinical findings, such as hemodynamic stability, and the results of the history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angina should always be considered as the underlying cause of chest discomfort in the patient undergoing dialysis given the increased incidence of coronary disease in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .) The appropriate history, physical examination, and, if clinically indicated, electrocardiogram and cardiac enzyme evaluation should therefore be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .) If dialysis is continued, the administration of oxygen and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , reduction of the desired ultrafiltration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood pump speed, and administration of nitrates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    should be considered on an individual basis.",
"   </p>",
"   <p>",
"    Angina during dialysis may be prevented with the administration of nitrates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta blockers prior to the treatment. However, the efficacy of these agents is diminished since they commonly result in hypotension, thereby reducing the ability to effectively remove extracellular fluid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolysis may present as chest pain, chest tightness, or back pain. It deserves consideration as an etiologic factor in the patient with these complaints, particularly if multiple individuals have such symptoms simultaneously. If hemolysis is not recognized early, severe hyperkalemia may ensue and lead to death.",
"   </p>",
"   <p>",
"    Findings highly suggestive of substantial hemolysis include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A port wine appearance of the blood in the venous line",
"     </li>",
"     <li>",
"      Complaints of chest pain, shortness of breath,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      back pain",
"     </li>",
"     <li>",
"      A falling hematocrit",
"     </li>",
"     <li>",
"      A pink color of the plasma in centrifuged specimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The etiology of hemolysis in hemodialysis patients is usually related to problems with the dialysis solution [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/1\">",
"     1",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overheating",
"     </li>",
"     <li>",
"      Hypotonicity due to an insufficient concentrate-to-water ratio",
"     </li>",
"     <li>",
"      Contamination with formaldehyde, bleach, chloramine, or nitrates from the water supply, and copper from copper tubing or piping.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=see_link\">",
"     \"Contaminants in water used for hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Red blood cell trauma due to improperly functioning roller clamps on dialysis machines, kinking of the blood lines, and poorly constructed blood tubing can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. Hemolysis may also be caused by bypassing arterial pillows, which are still utilized to monitor for excessive pressure in some dialysis units [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial treatment of suspected hemolysis in a patient on hemodialysis is to stop dialysis immediately, clamp the blood lines (do not return the blood to avoid increasing the risk of hyperkalemia), prepare to treat hyperkalemia and the potentially severe anemia, and investigate the cause. Patients require hospitalization for observation since life-threatening hyperkalemia may develop after dialysis has been terminated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link\">",
"     \"Clinical manifestations of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Air embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air embolism during dialysis is another cause of chest pain as well as other symptoms, particularly dyspnea. It can lead to death unless quickly detected and treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .) Fortunately, air embolism is rare in hemodialysis patients, in part because of the presence of air detectors in hemodialysis machines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/115?source=see_link\">",
"     \"Overview of the hemodialysis apparatus\"",
"    </a>",
"    .) Foam in the venous blood line should make one suspect that air is entering the dialysis system. Disconnection of connecting caps",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood lines can also lead to air embolism in patients being dialyzed with central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms due to an air embolism depend in part upon the patient's physical position at the time of the event. In the seated patient, air tends to migrate into the cerebral venous system without entering the heart; in those who are recumbent, air tends to first enter the heart and then the lungs. As a result, the seated patient with an air embolism may lose consciousness and seize, while the recumbent patient may initially develop dyspnea, cough, and perhaps chest tightness. Subsequent acute neurologic and cardiac dysfunction in the recumbent patient may be due to the direct passage of air into the arterial system, paradoxical embolization, or incomplete filtering of a large air embolus by the pulmonary capillaries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"     \"Seizures in patients undergoing hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of suspected air embolism includes clamping the venous line and stopping the blood pump. The patient should be positioned on the",
"    <strong>",
"     left side",
"    </strong>",
"    in a supine position with the chest and head tilted downward. Cardiorespiratory support, the administration of 100 percent oxygen by either mask or endotracheal tube, and attempted percutaneous aspiration of air from the ventricle may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/1\">",
"     1",
"    </a>",
"    ]. The most important aspect of air embolism is prevention; this is accomplished through the adequate function of monitoring devices on dialysis machines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of ventricular arrhythmias in dialysis patients has been evaluated by Holter monitoring. These arrhythmias are common during dialysis and between treatments; the published frequency ranges widely from 5 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. Supraventricular arrhythmias are also common [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/15,19,21\">",
"     15,19,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for arrhythmias and sudden death in dialysis patients include coronary artery disease, advanced age, myocardial dysfunction, and left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/15-19,21-27\">",
"     15-19,21-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11288?source=see_link\">",
"     \"Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with underlying autonomic dysfunction are also at greater risk of arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19684?source=see_link\">",
"     \"Autonomic dysfunction in dialysis patients\"",
"    </a>",
"    .) A higher prevalence of conduction defects, particularly first degree atrioventricular block and bundle branch block, has been associated with mitral valve or mitral annular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During hemodialysis, the incidence of arrhythmias may be enhanced because of rapid fluctuations in hemodynamics and electrolyte concentrations, as well as the induction of hypoxemia in patients with a high incidence of myocardial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/19\">",
"     19",
"    </a>",
"    ]. Studies examining the role of potassium in dialysis-induced arrhythmias are somewhat contradictory [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/30\">",
"     30",
"    </a>",
"    ], but new techniques may lead to a better understanding of the interactions of potassium, hemodialysis, and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/31\">",
"     31",
"    </a>",
"    ]. Some reports have found no relationship of plasma potassium to the development of arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], and the use of low potassium dialysate has been reported to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other studies have found a correlation between changes in the plasma potassium concentration during dialysis and the incidence of arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. One prospective, multicenter randomized study of 42 patients, for example, examined the incidence of ventricular arrhythmias with two different dialysate potassium concentration protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/34\">",
"     34",
"    </a>",
"    ]. One arm of the study was designed to maintain a constant plasma-to-dialysate potassium concentration gradient throughout the dialysis procedure, while the other protocol consisted of the standard constant dialysate potassium concentration which results in a varying potassium gradient. Treatment with the constant plasma-to-dialysate potassium gradient protocol resulted in 36 and 32 percent reductions in premature ventricular contractions per hour and ventricular couplets per hour during hemodialysis, respectively, compared with dialysis using a constant dialysate potassium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional study is needed to clarify the causes of arrhythmias during dialysis.",
"   </p>",
"   <p>",
"    The treatment of arrhythmias that occur in dialysis patients, either during or between dialysis sessions, is similar to their treatment in the nondialysis patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=see_link\">",
"     \"Arrhythmia management for the primary care clinician\"",
"    </a>",
"    .) However, appropriate dosing of medications based upon the absence of renal function is always required [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13274142\">",
"    <span class=\"h2\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may complain of shortness of breath while on hemodialysis. Most often, the dyspnea will occur as a result of volume overload and the patient will describe the dyspnea as occurring before the start of the hemodialysis treatment.",
"   </p>",
"   <p>",
"    However, dyspnea that begins after the initiation of hemodialysis should prompt consideration of other possible causes such as angina or acute coronary syndrome, bacteremia (associated with dialysis catheter), a reaction to the dialyzer, pericardial effusion with or without tamponade, or pneumonia.",
"   </p>",
"   <p>",
"    Medications administered with hemodialysis may be associated with dyspnea and should be considered, particularly intravenous iron which may rarely cause an allergic reaction, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , which can be associated with heparin-induced thrombocytopenia resulting in clotting in the dialyzer and lines and resultant hypoxia and a capillary leak syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of simultaneous symptoms (eg, fever, chills, hypotension, cough) often leads to the identification of the cause of the dyspnea. The timing of onset of dyspnea may also provide clues to its etiology. As an example, pulmonary embolism should be considered if dyspnea occurs after access declotting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8343/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent episodes of dyspnea occurring on dialysis are most likely to be associated with dialyzer reactions or, possibly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -associated effects. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       \"Patient information: Hemodialysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute complications commonly occur during routine hemodialysis treatments. They include hypotension, cramps, nausea and vomiting, headache, chest pain, back pain, itching, and fever and chills. These complications are generally caused by multiple underlying mechanisms and are poorly understood. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Longer treatment times",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrafiltration in association with a large degree of solute removal significantly enhance the incidence of headache, nausea, and vomiting during dialysis. A variant of the dialysis disequilibrium syndrome may underlie these symptoms in many patients. The syndrome should be considered in the noncompliant",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inadequately dialyzed patient who develops nausea, vomiting, or headache while being aggressively dialyzed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Headache, nausea, and vomiting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest pain that occurs while a patient is being dialyzed may be associated with hypotension, dialysis disequilibrium syndrome, angina, hemolysis, and (rarely) air embolism. Furthermore, although extremely uncommon, pulmonary embolism may be observed after manipulation of thrombus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occlusion of the dialysis access. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chest pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular arrhythmias are common during dialysis and between treatments; the published frequency ranges widely from 5 to 75 percent. Supraventricular arrhythmias are also common. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dyspnea on dialysis needs to be evaluated in the context of the patient&rsquo;s volume status, other symptoms, and medications. Cardiovascular, infectious, allergic reactions to dialyzer or medications, and hematologic disorders such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia should be considered. (See",
"      <a class=\"local\" href=\"#H13274142\">",
"       'Dyspnea'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bregman, H, Daugirdas, JT, Ing, TS. Complications during hemodialysis. In: Handbook of Dialysis, Daugirdas, JT, Ing, TS (Eds), Little, Brown, New York, 1994, p. 149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/2\">",
"      Dumler F, Stalla K, Mohini R, et al. Clinical experience with short-time hemodialysis. Am J Kidney Dis 1992; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/3\">",
"      Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM. Biocompatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after hemodialysis. ASAIO Trans 1990; 36:M637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/4\">",
"      Collins DM, Lambert MB, Tannenbaum JS, et al. Tolerance of hemodialysis: a randomized prospective trial of high-flux versus conventional high-efficiency hemodialysis. J Am Soc Nephrol 1993; 4:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/5\">",
"      Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM. Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis. Artif Organs 1994; 18:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/6\">",
"      Milinkovic M, Zidverc-Trajkovic J, Sternic N, et al. Hemodialysis headache. Clin Nephrol 2009; 71:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/7\">",
"      van Brussel MS, Koppius PW, Schut NH. Headache during hemodialysis - an uncommon cause for a common problem. Clin Nephrol 2008; 69:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/8\">",
"      Barrett BJ, Vavasour HM, Major A, Parfrey PS. Clinical and psychological correlates of somatic symptoms in patients on dialysis. Nephron 1990; 55:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/9\">",
"      Guntupalli K, Soffer O, Baciewicz P. Pulmonary embolism in end stage renal disease. Intensive Care Med 1990; 16:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/10\">",
"      Hombrouckx R, D'Halluin F, Bogaert AM, et al. Fibrin sheet covering subclavian or femoral dialysis catheters. Artif Organs 1994; 18:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/11\">",
"      Sweet SJ, McCarthy S, Steingart R, Callahan T. Hemolytic reactions mechanically induced by kinked hemodialysis lines. Am J Kidney Dis 1996; 27:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/12\">",
"      Duffy R, Tomashek K, Spangenberg M, et al. Multistate outbreak of hemolysis in hemodialysis patients traced to faulty blood tubing sets. Kidney Int 2000; 57:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/13\">",
"      Francos GC, Burke JF Jr, Besarab A, et al. An unsuspected cause of acute hemolysis during hemodialysis. Trans Am Soc Artif Intern Organs 1983; 29:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/14\">",
"      Aqeel, A, Kissner, PZ, Sondheimer, JH. Air embolism in hemodialysis: An old problem revisited (abstract). J Am Soc Nephrol 1998; 9:165A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/15\">",
"      Wander GS, Sandha GS, Chhabra SC, et al. Holter monitoring in chronic renal failure before &amp; during dialysis. J Assoc Physicians India 1994; 42:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/16\">",
"      De Lima JJ, Lopes HF, Grupi CJ, et al. Blood pressure influences the occurrence of complex ventricular arrhythmia in hemodialysis patients. Hypertension 1995; 26:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/17\">",
"      Sarogca, MA, Canziani, ME, Cassiolato, JL, et al. Left ventricular hypertrophy as a risk factor for arrhythmias in hemodialysis patients. J Cardiovasc Pharmacol 1992; 17(Suppl 2):S136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/18\">",
"      Multicentre, cross-sectional study of ventricular arrhythmias in chronically haemodialysed patients. Gruppo Emodialisi e Patologie Cardiovasculari. Lancet 1988; 2:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/19\">",
"      Munger MA, Ateshkadi A, Cheung AK, et al. Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers. Am J Kidney Dis 2000; 36:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/20\">",
"      Voroneanu L, Covic A. Arrhythmias in hemodialysis patients. J Nephrol 2009; 22:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/21\">",
"      Shapira OM, Bar-Khayim Y. ECG changes and cardiac arrhythmias in chronic renal failure patients on hemodialysis. J Electrocardiol 1992; 25:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/22\">",
"      Morris ST, Galiatsou E, Stewart GA, et al. QT dispersion before and after hemodialysis. J Am Soc Nephrol 1999; 10:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/23\">",
"      de Lima JJ, Vieira ML, Lopes HF, et al. Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis, and renal transplant patients. Am J Hypertens 1999; 12:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/24\">",
"      Narula AS, Jha V, Bali HK, et al. Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren Fail 2000; 22:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/25\">",
"      Fabbian F, Catalano C, Lambertini D, et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol 2000; 54:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/26\">",
"      Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int 2001; 60:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/27\">",
"      Kitano Y, Kasuga H, Watanabe M, et al. Severe coronary stenosis is an important factor for induction and lengthy persistence of ventricular arrhythmias during and after hemodialysis. Am J Kidney Dis 2004; 44:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/28\">",
"      Jassal SV, Coulshed SJ, Douglas JF, Stout RW. Autonomic neuropathy predisposing to arrhythmias in hemodialysis patients. Am J Kidney Dis 1997; 30:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/29\">",
"      Shurmur SW, D'Elia JA, Gleason RE, et al. Cardiac conduction defects associated with aortic and mitral valve calcification in dialysis patients. Ren Fail 1990; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/30\">",
"      Locatelli F, Covic A, Chazot C, et al. Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant 2004; 19:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/31\">",
"      Buemi M, Coppolino G, Bolignano D, et al. Arrhythmias and hemodialysis: role of potassium and new diagnostic tools. Ren Fail 2009; 31:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/32\">",
"      Hou S, McElroy PA, Nootens J, Beach M. Safety and efficacy of low-potassium dialysate. Am J Kidney Dis 1989; 13:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/33\">",
"      Rombol&agrave; G, Colussi G, De Ferrari ME, et al. Cardiac arrhythmias and electrolyte changes during haemodialysis. Nephrol Dial Transplant 1992; 7:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/34\">",
"      Redaelli B, Locatelli F, Limido D, et al. Effect of a new model of hemodialysis potassium removal on the control of ventricular arrhythmias. Kidney Int 1996; 50:609.",
"     </a>",
"    </li>",
"    <li>",
"     Weiner, DE, Nicholls, AJ, Sarnak, MJ. Cardiovascular disease. In: Handbook of Dialysis, Daugirdas, JT, Blake, PG, Ing, TS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. p. 626.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/36\">",
"      Kapa S, Qian Q. 84-year-old woman with hemodialysis-associated shortness of breath. Mayo Clin Proc 2009; 84:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8343/abstract/37\">",
"      Grebenyuk LA, Marcus RJ, Nahum E, et al. Pulmonary embolism following successful thrombectomy of an arteriovenous dialysis fistula. J Vasc Access 2009; 10:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1881 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8343=[""].join("\n");
var outline_f8_9_8343=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEADACHE, NAUSEA, AND VOMITING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHEST PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13274142\">",
"      Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=related_link\">",
"      Arrhythmia management for the primary care clinician",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19684?source=related_link\">",
"      Autonomic dysfunction in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=related_link\">",
"      Contaminants in water used for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11288?source=related_link\">",
"      Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36325?source=related_link\">",
"      Muscle cramps in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/115?source=related_link\">",
"      Overview of the hemodialysis apparatus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=related_link\">",
"      Seizures in patients undergoing hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_9_8344="Spinal muscular atrophy";
var content_f8_9_8344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"20\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spinal muscular atrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8344/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8344/contributors\">",
"     Olaf A Bodamer, MD, FACMG, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8344/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8344/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8344/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8344/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8344/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/9/8344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular disorders that present in the newborn period with hypotonia and weakness are caused by a variety of conditions that affect the central nervous system (brain or spinal cord), peripheral nervous system, or skeletal muscle. Conditions that affect the anterior horn cells of the spinal cord are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef66572 \" href=\"UTD.htm?27/44/28365\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review clinical aspects of spinal muscular atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal muscular atrophy (SMA) disorders are characterized by degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem. These diseases are classified as types 1 through 4 depending upon the age of onset and clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;SMA type 1, also known as infantile spinal muscular atrophy or Werdnig-Hoffmann disease, is the most common and severe type of SMA. It typically presents in the neonatal period. However, mothers of affected patients may recognize a decrease or loss of fetal movement in late pregnancy. Some experts classify prenatal onset as SMA type 0 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In these neonatal forms, symptoms progress rapidly, and the majority of infants die before one year of age from respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Nevertheless, long-term survivors have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This is perhaps due, in part, to advances in the care of chronic respiratory insufficiency and to more aggressive care. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SMA 2 (intermediate form) and SMA 3 (mild form; Kugelberg-Welander disease) have a later onset and a less severe course [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. SMA 2 presents between 3 and 15 months of age, whereas SMA 3, the least severe, typically presents with signs of weakness at or after one year of age and progresses to a chronic course. In a study of children and adolescents with SMA 2 and SMA 3, muscle strength was reduced to a variable extent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/10\">",
"     10",
"    </a>",
"    ]. Although the muscle weakness affected motor function, walking, transfer from lying or sitting to the standing position, and stair-climbing were possible in some children. The outcome depends primarily upon the severity of muscle weakness at presentation rather than the age of onset, but earlier onset tends to correlate with greater weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult onset of SMA (type 4) usually presents in the second or third decade of life and is otherwise similar to SMA type 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with all forms of SMA have diffuse symmetric proximal muscle weakness that is greater in the lower than upper limbs and absent or markedly decreased deep tendon reflexes. Infants with SMA 1 have a severe symmetric flaccid paralysis and are unable to sit unsupported. Arthrogryposis (multiple joint contractures) may occasionally be present in those with a prenatal onset, which is sometimes classified as SMA 0. Because the upper cranial nerves are spared, patients with SMA 1 typically have an alert expression, furrowed brow, and normal eye movements. However, weakness of the bulbar muscles results in a weak cry, poor suck and swallow reflexes, pooling of secretions, aspiration, and fasciculations of the tongue.",
"   </p>",
"   <p>",
"    All SMA types are associated with a restrictive, progressive respiratory insufficiency, particularly SMA 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/16\">",
"     16",
"    </a>",
"    ]. In SMA 1, respiratory muscle weakness leads to progressive respiratory failure. The intercostal muscles typically are more affected than the diaphragm, resulting in paradoxical breathing (inspiratory efforts cause the rib cage to move inward and the abdomen to move outward) and the development of a characteristic bell-shaped chest deformity. Cardiac muscle is not affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inheritance pattern of 5q-related SMAs is autosomal recessive [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. The different forms of 5q-SMA are caused by biallelic deletions or mutations in the survival motor neuron 1 (SMN1) gene on chromosome 5q13.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The most common mutation of the SMN1 gene is a deletion of exon 7 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/21\">",
"     21",
"    </a>",
"    ]. Approximately 94 percent of patients with clinically typical SMA carry homozygous deletions of exon 7. SMN protein appears to play a role in mRNA synthesis in motor neurons and also may inhibit apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The level of SMN protein correlates with severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differences in SMN protein and phenotypic expression appear to be related in part to a modifying gene, called SMN2. The SMN1 and SMN2 genes are more than 99 percent identical and lie within an inverted duplication on chromosome 5q13.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/25\">",
"     25",
"    </a>",
"    ]. The SMN1 gene lies telomeric of the SMN2 gene. Loss of the SMN1 protein is partially compensated by SMN2 protein synthesis, a mechanism that may explain some but not all of the phenotypic variability in patients with SMA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/26\">",
"     26",
"    </a>",
"    ]. The presence of three or more copies of SMN2 is associated with a milder phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/15,27\">",
"     15,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the most common forms of SMA are caused by deletions or mutations in the SMN1 gene on chromosome 5q (ie, 5q SMAs), there are a number of rare non-5q spinal muscular atrophies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The non-5q SMAs are genetically and clinically heterogeneous (",
"    <a class=\"graphic graphic_table graphicRef73754 \" href=\"UTD.htm?14/8/14478\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with SMA should be referred for genetic counseling, which may be challenging. Occasionally, carriers have normal dosage studies for the SMN1 deletion because they have a deletion on one homologue and a SMN1 gene duplication on the other. There is also a significant de novo mutation rate (1.7 percent).",
"   </p>",
"   <p>",
"    Genetic counseling, prenatal diagnosis, and carrier testing can be offered to those with a family history of SMA (or SMA-like disorders) in whom the genetic basis of the condition has been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/30\">",
"     30",
"    </a>",
"    ]. However, there is no consensus regarding the utility of preconception and prenatal screening for SMA in those without a family history. The American College of Medical Genetics recommends offering carrier testing to all couples regardless of race or ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In contrast, the American College of Obstetricians and Gynecologists (ACOG) states that such screening is NOT recommended in the general population at this time, but should be offered to those who first have genetic counseling that includes discussion of the sensitivity, specificity, and limitations of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular genetic testing with targeted mutation analysis can confirm the diagnosis of SMA by detection of homozygous deletions of the telomeric exons 7 and 8 of the SMN1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/1,15,33\">",
"     1,15,33",
"    </a>",
"    ]. The exon 7 deletion is by far the most common mutation in SMA, but point mutations also occur. Thus, sequencing of the SMN1 gene should be pursued if the diagnosis is typical of SMA and only a single deletion is identified.",
"   </p>",
"   <p>",
"    In patients with suspected SMA who have a normal SMN1 gene by molecular genetic testing, the diagnosis of SMA is made clinically by electromyography and nerve conduction studies, and confirmed by muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/15\">",
"     15",
"    </a>",
"    ]. Nevertheless, absence of a deletion in SMN1 casts serious doubt on the diagnosis. In this situation, it is imperative to consider other conditions in the differential diagnosis (eg, spinal muscular atrophy with respiratory distress type 1)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sequencing of the SMN1 gene. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography in SMA shows abnormal spontaneous activity with fibrillations and positive sharp waves [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The mean duration and amplitude of motor unit action potentials are increased, and many are polyphasic. Nerve conduction velocities are normal or slightly decreased, and sensory nerve action potentials are normal. Serum creatine kinase concentration typically is normal or slightly elevated, although in rare cases it can be moderately elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy reveals large groups of circular atrophic type 1 and 2 muscle fibers interspersed among fascicles of hypertrophied type 1 fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/34\">",
"     34",
"    </a>",
"    ]. The enlarged fibers have been reinnervated by the sprouting of surviving nerves and are three to four times larger than normal. Histologic diagnosis may be more difficult to make in the newborn infant because only widespread atrophy of muscle fibers may be seen. A later repeat biopsy is needed to demonstrate the mixture of hypertrophied and atrophic fibers seen after reinnervation occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of infantile SMA (types 0 and 1) includes other causes of floppy (hypotonic) infants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/15\">",
"     15",
"    </a>",
"    ]. Conditions that affect the anterior horn cells of the spinal cord are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef66572 \" href=\"UTD.htm?27/44/28365\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Arthrogryposis multiplex congenita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthrogryposis multiplex congenita is a syndrome characterized by contractures of multiple joints [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. It is associated with a heterogeneous group of disorders. Most cases are neurogenic (90 of 96 children in one study of pathologic features); the remaining cases have primary muscle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/38\">",
"     38",
"    </a>",
"    ]. Neurogenic arthrogryposis can result from disorders of the central nervous system, genetic syndromes, and chromosomal aberrations. The severity is variable. Bulbar and respiratory muscle functions are severely affected in some cases, which have a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/39\">",
"     39",
"    </a>",
"    ]. In others, muscle strength does not deteriorate and may improve.",
"   </p>",
"   <p>",
"    The disorders that result in neurogenic arthrogryposis are genetically heterogeneous. Some patients (6 of 12 in one series) have deletions of the SMN1 gene that is associated with SMA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     X-linked infantile spinal muscular atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked infantile spinal muscular atrophy (XL-SMA or SMAX2) is a rare disorder characterized by congenital hypotonia, areflexia, congenital contractures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fractures, and loss of anterior horn cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The disease course in XL-SMA is similar to the severe forms of classic neonatal SMA (SMA types 0 and 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/43\">",
"     43",
"    </a>",
"    ]. The disorder is associated with mutations in the gene for ubiquitin activating enzyme 1 (called UBA1 gene or UBE1 gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Spinal muscular atrophy with respiratory distress type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal muscular atrophy with respiratory distress type 1 (SMARD1), also known as autosomal recessive distal spinal muscular atrophy 1 (DSMA1), is characterized by diaphragmatic paralysis and respiratory failure that presents early in life, generally from one to six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. There is a high frequency of intrauterine growth retardation and premature birth. Eventration of the diaphragm may be seen on chest radiographs. Clinical deterioration continues for the first two years of life, followed by stabilization or less often by some clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/46\">",
"     46",
"    </a>",
"    ]. While all affected children remain dependent on mechanical ventilation and require full time care, some are able to participate in daily life activities and schooling. The disorder is caused by mutations in the immunoglobulin mu binding protein 2 (IGHMBP2) gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Congenital myasthenic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with congenital myasthenia frequently have ptosis, in contrast to patients with the transient disorder. In addition, they typically demonstrate ophthalmoplegia and bulbar and respiratory muscle weakness. Affected infants may have fluctuating generalized hypotonia, weakness, and life-threatening episodes of apnea. Arthrogryposis can be present at birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link&amp;anchor=H7#H7\">",
"     \"Neuromuscular junction disorders in newborns and infants\", section on 'Congenital myasthenic syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Congenital myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital myopathies (eg, nemaline myopathy, central core disease, myotubular myopathy, and congenital fiber type disproportion) present with hypotonia and weakness that is greater proximally than distally. Tendon reflexes are decreased in proportion to the weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link\">",
"     \"Congenital myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypoxic-ischemic myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypoxic-ischemic injury can sometimes result in hypotonia or flaccid paralysis with diminished or absent reflexes caused by death of spinal motor neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/47\">",
"     47",
"    </a>",
"    ]. In these cases, infants typically have encephalopathy and may have seizures or signs of other end-organ damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glycogen storage disease II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic infantile form of glycogen storage disease II (Pompe disease) is characterized by hypertrophic cardiomyopathy and severe generalized muscular hypotonia that presents during the first few months of life. The tongue may be enlarged. Hepatomegaly also may be present and is usually due to heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=see_link\">",
"     \"Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prader-Willi syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal hypotonia is one of the hallmark features of Prader-Willi syndrome. The profound hypotonia can lead to asphyxia. Affected infants often have feeding difficulties, including a poor suck, which may lead to failure to thrive. Other common features include a weak cry and genital hypoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hypotonia associated with Prader-Willi syndrome improves gradually during infancy, unlike SMA type 1 in which progressive deterioration occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Traumatic myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelopathy caused by trauma to the high cervical spinal cord is a rare cause of hypotonia in infants. This condition results in a flaccid paralysis, which may be asymmetric, and absent reflexes. Physical examination may reveal evidence of trauma, such as bruising or fractures. If no accompanying brain injury is present, the infant will be alert with no cranial nerve abnormalities. A pin prick on the face will elicit a facial grimace but no response below the neck. A useful sign is withdrawal to a noxious stimulus of a limb with no spontaneous activity. Bladder distension, priapism, and absence of sweating below the level of the spinal lesion typically will appear as the myelopathy evolves over several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Zellweger syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with Zellweger syndrome present with a characteristic craniofacial dysmorphism. Neurologic abnormalities include hypotonia and weakness with absent reflexes, severe impairment of hearing and vision, neonatal seizures, and developmental delay. Hepatomegaly is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H17#H17\">",
"     \"Peroxisomal disorders\", section on 'Zellweger syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for SMA is supportive and directed at providing nutrition and respiratory assistance as needed, and treating or preventing complications of weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/48\">",
"     48",
"    </a>",
"    ]. Physical therapy may be helpful. Spinal bracing can be used to delay the development of progressive scoliosis that is caused by muscle weakness. However, spinal bracing applied to patients with SMA types 1 or 2 while in the sitting position significantly reduces expiratory tidal volume, and thus it should be used cautiously [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory muscle weakness often results in difficulty clearing lower respiratory secretions and hypoventilation during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/50\">",
"     50",
"    </a>",
"    ]. Important interventions include methods for mobilization and clearance of airway secretions, and respiratory support.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secretion mobilization and clearance techniques involve manual or mechanical chest physiotherapy with postural drainage, and manual cough assistance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      use of a mechanical",
"      <span class=\"nowrap\">",
"       insufflation/exsufflation",
"      </span>",
"      device [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Noninvasive nasal ventilation is an alternative to tracheostomy and conventional ventilator support in some children with respiratory failure [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/16,51,52\">",
"       16,51,52",
"      </a>",
"      ]. Decisions about initiating ventilator support should be individualized, taking into account the medical facts and the values of the family [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited data suggest that survival has increased in patients with SMA type 1 born from 1995 through 2006 compared with those born from 1980 to 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/7\">",
"     7",
"    </a>",
"    ]. Ventilation for &gt;16 hours a day, use of mechanical insufflation-exsufflation device, and gastrostomy tube feeding were significantly and independently associated with prolonged survival, while year of birth was not. Thus, longer survival in the later time period appears to be related to more aggressive care.",
"   </p>",
"   <p>",
"    Treatments that enhance the level of SMN protein may be available in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. One potential agent is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    , which can alter SMN2 gene transcription and increase SMN protein in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/56\">",
"     56",
"    </a>",
"    ]. In a preliminary open label study, strength improved in seven adult patients with SMA who were treated with valproate for a mean duration of eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/57\">",
"     57",
"    </a>",
"    ]. However, in another open label study of 42 patients with SMA who completed at least six months of valproate treatment, depletion of total or free plasma",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    was frequent and was temporally associated with increased weakness in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/58\">",
"     58",
"    </a>",
"    ]. Weight gain was also common, while improvement in motor scores was limited to children younger than five years of age.",
"   </p>",
"   <p>",
"    Gene therapy using an adeno-associated virus vector to augment spinal cord SMN expression has shown promise in a mouse model of SMA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/59\">",
"     59",
"    </a>",
"    ]. Another promising approach involves intracerebroventricular or systemic injection of antisense oligonucleotides that effectively restore SMN expression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenylbutyrate appeared promising in preclinical studies, but did not improve outcomes of children with SMA type 2 in a randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted earlier, all SMA types are associated with a restrictive, progressive respiratory insufficiency. Thus, pregnancy in women with SMA is associated with increased risk because of impaired respiratory function, which is further limited in many cases by kyphoscoliosis and wheel chair dependency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, limited retrospective data suggest that pregnancy in women with SMA is often complicated by preterm labor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/65\">",
"     65",
"    </a>",
"    ] and an increased frequency of urinary tract infections [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these issues, no deleterious effects have been detected with respect to fetal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Successful pregnancies have been reported in women with SMA who have forced vital capacities of 50 to 70 percent of predicted values [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideally, such pregnancies should be managed by obstetricians and anesthesiologists familiar with neuromuscular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/64\">",
"     64",
"    </a>",
"    ]. There are no guidelines regarding mode of delivery. Successful outcomes have been reported with both cesarean section and vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Spinal and epidural anesthesia may be difficult because of severe spine deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/66\">",
"     66",
"    </a>",
"    ]. However, there is no evidence of an increased risk of malignant hyperthermia in SMA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with SMA may experience worsening of muscle weakness after the second trimester",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed postpartum recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/65,68\">",
"     65,68",
"    </a>",
"    ]. In one report, an uneventful pregnancy and cesarean section was followed by extreme muscle weakness with dyspnea and bulbar involvement lasting one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8344/abstract/68\">",
"     68",
"    </a>",
"    ]. Motor function then improved to baseline.",
"   </p>",
"   <p>",
"    Issues related to prenatal screening are discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Genetic screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spinal muscular atrophy (SMA) disorders are characterized by degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem. These diseases are classified as types 1 through 4 depending upon the age of onset and clinical course (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      SMA type 1 (infantile spinal muscular atrophy or Werdnig-Hoffmann disease) is the most common and severe type of SMA. It typically presents in the neonatal period. Symptoms progress rapidly, and the majority of infants die before one year of age from respiratory failure.",
"     </li>",
"     <li>",
"      SMA type 2 (intermediate form) and type 3 (Kugelberg-Welander disease) have a less severe course. SMA 2 presents between three and 15 months of age. SMA 3, the least severe, typically presents at or after one year of age and progresses to a chronic course.",
"     </li>",
"     <li>",
"      Adult onset of SMA (type 4) usually presents in the second or third decade of life and is otherwise similar to SMA type 3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with all forms of SMA have diffuse symmetric proximal muscle weakness that is greater in the lower than upper limbs and absent or markedly decreased deep tendon reflexes. Infants with SMA 1 have a severe symmetric flaccid paralysis and are unable to sit unsupported. All SMA types, particularly SMA 1, are associated with a restrictive, progressive respiratory insufficiency. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The inheritance pattern of the SMAs is autosomal recessive. The different forms of SMA are caused by biallelic deletions or mutations in the SMN1 gene on chromosome 5q13. The differences in SMN protein and phenotypic expression appear to be related in part to a modifying gene &mdash; SMN2 &mdash; that lies close to the SMN1 gene. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Molecular genetic testing can confirm the diagnosis in infants and children with suspected SMA. In patients with suspected SMA who have a normal SMN1 gene by molecular genetic testing, the diagnosis of SMA is made clinically by electromyography, nerve conduction studies, and muscle biopsy. Nevertheless, absence of a deletion in SMN1 casts serious doubt on the diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of infantile SMA (types 0 and 1) includes other causes of floppy infants. Of particular importance are the following conditions (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arthrogryposis multiplex congenita",
"     </li>",
"     <li>",
"      X-linked infantile spinal muscular atrophy",
"     </li>",
"     <li>",
"      Spinal muscular atrophy with respiratory distress type 1",
"     </li>",
"     <li>",
"      Congenital myasthenic syndromes",
"     </li>",
"     <li>",
"      Congenital myopathies",
"     </li>",
"     <li>",
"      Hypoxic-ischemic myelopathy",
"     </li>",
"     <li>",
"      Lysosomal acid maltase deficiency",
"     </li>",
"     <li>",
"      Prader-Willi syndrome",
"     </li>",
"     <li>",
"      Traumatic myelopathy",
"     </li>",
"     <li>",
"      Zellweger syndrome",
"      <br/>",
"      <br/>",
"      Conditions that affect the anterior horn cells of the spinal cord are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef66572 \" href=\"UTD.htm?27/44/28365\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment for SMA is supportive and directed at providing nutrition and respiratory assistance as needed, and treating or preventing complications of weakness. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/1\">",
"      Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 2012; 11:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/2\">",
"      Munsat TL, Davies KE. International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul Disord 1992; 2:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/3\">",
"      Thomas NH, Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord 1994; 4:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/4\">",
"      Farrar MA, Vucic S, Johnston HM, et al. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr 2013; 162:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/5\">",
"      Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics 2004; 114:e548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/6\">",
"      Zerres K, Rudnik-Sch&ouml;neborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995; 52:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/7\">",
"      Oskoui M, Levy G, Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology 2007; 69:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/8\">",
"      Lefebvre S, B&uuml;rglen L, Fr&eacute;zal J, et al. The role of the SMN gene in proximal spinal muscular atrophy. Hum Mol Genet 1998; 7:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/9\">",
"      Kaufmann P, McDermott MP, Darras BT, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 2012; 79:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/10\">",
"      Kroksmark AK, Beckung E, Tulinius M. Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. Eur J Paediatr Neurol 2001; 5:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/11\">",
"      Rudnik-Sch&ouml;neborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K. The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 2001; 45:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/12\">",
"      Brahe C, Servidei S, Zappata S, et al. Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy. Lancet 1995; 346:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/13\">",
"      Clermont O, Burlet P, Lefebvre S, et al. SMN gene deletions in adult-onset spinal muscular atrophy. Lancet 1995; 346:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/14\">",
"      Zerres K, Rudnik-Sch&ouml;neborn S, Forkert R, Wirth B. Genetic basis of adult-onset spinal muscular atrophy. Lancet 1995; 346:1162.",
"     </a>",
"    </li>",
"    <li>",
"     Prior TW, Russman BS. Spinal muscular atrophy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1352/ (Accessed on January 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/16\">",
"      Ioos C, Leclair-Richard D, Mrad S, et al. Respiratory capacity course in patients with infantile spinal muscular atrophy. Chest 2004; 126:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/17\">",
"      Scheffer H, Cobben JM, Matthijs G, Wirth B. Best practice guidelines for molecular analysis in spinal muscular atrophy. Eur J Hum Genet 2001; 9:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/18\">",
"      Schmalbruch H, Haase G. Spinal muscular atrophy: present state. Brain Pathol 2001; 11:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/19\">",
"      Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998; 95:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/20\">",
"      Cusc&oacute; I, Barcel&oacute; MJ, del R&iacute;o E, et al. Detection of novel mutations in the SMN Tudor domain in type I SMA patients. Neurology 2004; 63:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/21\">",
"      Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet 2002; 111:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/22\">",
"      Friesen WJ, Massenet S, Paushkin S, et al. SMN, the product of the spinal muscular atrophy gene, binds preferentially to dimethylarginine-containing protein targets. Mol Cell 2001; 7:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/23\">",
"      Kerr DA, Nery JP, Traystman RJ, et al. Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci U S A 2000; 97:13312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/24\">",
"      Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/25\">",
"      Lefebvre S, B&uuml;rglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/26\">",
"      Hsieh-Li HM, Chang JG, Jong YJ, et al. A mouse model for spinal muscular atrophy. Nat Genet 2000; 24:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/27\">",
"      Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002; 4:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/28\">",
"      Zerres K, Rudnik-Sch&ouml;neborn S. 93rd ENMC international workshop: non-5q-spinal muscular atrophies (SMA) - clinical picture (6-8 April 2001, Naarden, The Netherlands). Neuromuscul Disord 2003; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/29\">",
"      Darras BT. Non-5q spinal muscular atrophies: the alphanumeric soup thickens. Neurology 2011; 77:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/30\">",
"      ACOG Committee on Genetics. ACOG committee opinion No. 432: spinal muscular atrophy. Obstet Gynecol 2009; 113:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/31\">",
"      Prior TW, Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med 2008; 10:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/32\">",
"      Prior TW. Spinal muscular atrophy: a time for screening. Curr Opin Pediatr 2010; 22:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/33\">",
"      Prior TW. Spinal muscular atrophy diagnostics. J Child Neurol 2007; 22:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/34\">",
"      Buchthal F, Olsen PZ. Electromyography and muscle biopsy in infantile spinal muscular atrophy. Brain 1970; 93:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/35\">",
"      Hausmanowa-Petrusewicz I, Karwa��ska A. Electromyographic findings in different forms of infantile and juvenile proximal spinal muscular atrophy. Muscle Nerve 1986; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/36\">",
"      Gordon N. Arthrogryposis multiplex congenita. Brain Dev 1998; 20:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/37\">",
"      O'Flaherty P. Arthrogryposis multiplex congenita. Neonatal Netw 2001; 20:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/38\">",
"      Banker BQ. Arthrogryposis multiplex congenita: spectrum of pathologic changes. Hum Pathol 1986; 17:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/39\">",
"      Bianchi DW, Van Marter LJ. An approach to ventilator-dependent neonates with arthrogryposis. Pediatrics 1994; 94:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/40\">",
"      B&uuml;rglen L, Amiel J, Viollet L, et al. Survival motor neuron gene deletion in the arthrogryposis multiplex congenita-spinal muscular atrophy association. J Clin Invest 1996; 98:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/41\">",
"      Bingham PM, Shen N, Rennert H, et al. Arthrogryposis due to infantile neuronal degeneration associated with deletion of the SMNT gene. Neurology 1997; 49:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/42\">",
"      Kobayashi H, Baumbach L, Matise TC, et al. A gene for a severe lethal form of X-linked arthrogryposis (X-linked infantile spinal muscular atrophy) maps to human chromosome Xp11.3-q11.2. Hum Mol Genet 1995; 4:1213.",
"     </a>",
"    </li>",
"    <li>",
"     Reardon LB, Sacharow S, Ahearn ME. Spinal muscular atrophy, X-linked infantile. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK2594/ (Accessed on January 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/44\">",
"      Dressman D, Ahearn ME, Yariz KO, et al. X-linked infantile spinal muscular atrophy: clinical definition and molecular mapping. Genet Med 2007; 9:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/45\">",
"      Grohmann K, Varon R, Stolz P, et al. Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Ann Neurol 2003; 54:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/46\">",
"      Eckart M, Guenther UP, Idkowiak J, et al. The natural course of infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Pediatrics 2012; 129:e148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/47\">",
"      Clancy RR, Sladky JT, Rorke LB. Hypoxic-ischemic spinal cord injury following perinatal asphyxia. Ann Neurol 1989; 25:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/48\">",
"      Iannaccone ST. Modern management of spinal muscular atrophy. J Child Neurol 2007; 22:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/49\">",
"      Tangsrud SE, Carlsen KC, Lund-Petersen I, Carlsen KH. Lung function measurements in young children with spinal muscle atrophy; a cross sectional survey on the effect of position and bracing. Arch Dis Child 2001; 84:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/50\">",
"      Schroth MK. Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics 2009; 123 Suppl 4:S245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/51\">",
"      Bach JR, Niranjan V, Weaver B. Spinal muscular atrophy type 1: A noninvasive respiratory management approach. Chest 2000; 117:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/52\">",
"      Chatwin M, Bush A, Simonds AK. Outcome of goal-directed non-invasive ventilation and mechanical insufflation/exsufflation in spinal muscular atrophy type I. Arch Dis Child 2011; 96:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/53\">",
"      Hardart MK, Truog RD. Spinal muscular atrophy--type I. Arch Dis Child 2003; 88:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/54\">",
"      Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy and therapeutic prospects. Prog Mol Subcell Biol 2006; 44:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/55\">",
"      Darras BT, Kang PB. Clinical trials in spinal muscular atrophy. Curr Opin Pediatr 2007; 19:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/56\">",
"      Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003; 54:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/57\">",
"      Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006; 67:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/58\">",
"      Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009; 4:e5268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/59\">",
"      Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010; 120:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/60\">",
"      Porensky PN, Mitrpant C, McGovern VL, et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 2012; 21:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/61\">",
"      Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/62\">",
"      MacKenzie A. Sense in antisense therapy for spinal muscular atrophy. N Engl J Med 2012; 366:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/63\">",
"      Mercuri E, Bertini E, Messina S, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007; 68:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/64\">",
"      Argov Z, de Visser M. What we do not know about pregnancy in hereditary neuromuscular disorders. Neuromuscul Disord 2009; 19:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/65\">",
"      Rudnik-Sch&ouml;neborn S, Zerres K, Ignatius J, Rietschel M. Pregnancy and spinal muscular atrophy. J Neurol 1992; 239:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/66\">",
"      Carter GT, Bonekat HW, Milio L. Successful pregnancies in the presence of spinal muscular atrophy: two case reports. Arch Phys Med Rehabil 1994; 75:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/67\">",
"      Pugh CP, Healey SK, Crane JM, Young D. Successful pregnancy and spinal muscular atrophy. Obstet Gynecol 2000; 95:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/68\">",
"      Rudnik-Sch&ouml;neborn S, Breuer C, Zerres K. Stable motor and lung function throughout pregnancy in a patient with infantile spinal muscular atrophy type II. Neuromuscul Disord 2002; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8344/abstract/69\">",
"      Yim R, Kirschner K, Murphy E, et al. Successful pregnancy in a patient with spinal muscular atrophy and severe kyphoscoliosis. Am J Phys Med Rehabil 2003; 82:222.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6146 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8344=[""].join("\n");
var outline_f8_9_8344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Arthrogryposis multiplex congenita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      X-linked infantile spinal muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Spinal muscular atrophy with respiratory distress type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Congenital myasthenic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Congenital myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypoxic-ischemic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glycogen storage disease II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Traumatic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Zellweger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/44/28365\" title=\"table 1\">",
"      Newborn neuromuscular disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/8/14478\" title=\"table 2\">",
"      Classification of non-5q SMAs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=related_link\">",
"      Congenital myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=related_link\">",
"      Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_9_8345="Dietary therapy for obesity";
var content_f8_9_8345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dietary therapy for obesity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8345/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8345/contributors\">",
"     George A Bray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8345/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8345/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8345/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/9/8345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/9/8345/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/9/8345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of overweight and obesity requires a combination of diet, exercise, and behavioral modification. In addition, some patients eventually require pharmacologic therapy or bariatric surgery. The risk of overweight to the subject should be evaluated before beginning any treatment program. Selection of treatment can then be made using a risk-benefit assessment (",
"    <a class=\"graphic graphic_figure graphicRef78307 \" href=\"UTD.htm?15/26/15778\">",
"     figure 1",
"    </a>",
"    ). The choice of therapy is dependent on several factors including the degree of overweight or obesity and patient preference.",
"   </p>",
"   <p>",
"    This topic will review the dietary therapy of obesity. Other aspects of treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to set goals when discussing a dietary weight loss program with an individual patient. An initial weight loss goal of 5 to 7 percent of body weight is realistic for most individuals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first goal for any overweight individual is to prevent further weight gain and keep body weight stable (within 5 pounds of its current level).",
"     </li>",
"     <li>",
"      The goal of the clinician is to identify and review with the patient a realistic weight loss goal. Most patients have a weight loss goal of 30 percent or more below current weight, which is unrealistic [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A successful program will lead to a weight loss of more than 5 percent of initial weight [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/2\">",
"       2",
"      </a>",
"      ]. A weight loss of more than 5 percent can reduce risk factors for cardiovascular disease, such as dyslipidemia, hypertension, and diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/3\">",
"       3",
"      </a>",
"      ]. In the Diabetes Prevention Program, a multi-center trial in patients with impaired glucose tolerance, weight loss of 7 percent reduced the rate of progression from impaired glucose tolerance to diabetes by 58 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H14#H14\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Diabetes Prevention Program'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Loss of 5 percent of initial body weight and maintenance of this loss is a good medical result, even if the subject does not reach his or her \"dream\" weight.",
"     </li>",
"     <li>",
"      Although an extremely difficult goal to achieve, a body mass index (BMI) between 20 and 25",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      puts the subject in the lowest risk category (",
"      <a class=\"graphic graphic_table graphicRef70466 \" href=\"UTD.htm?20/13/20700\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef78307 \" href=\"UTD.htm?15/26/15778\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIETARY ENERGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rate of weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of weight loss is directly related to the difference between the subject's energy intake and energy requirements. Reducing caloric intake below expenditure results in a predictable initial rate of weight loss that is related to the energy deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/5\">",
"     5",
"    </a>",
"    ]. However, prediction of weight loss for an individual subject can be difficult because of marked intersubject variability in initial body composition, adherence, and energy expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Food records are often inaccurate. Most normal-weight people under-report what they eat by 10 to 30 percent, while overweight people under-report by 30 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, energy requirements are influenced by fidgeting, gender, age, and genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men lose more weight than women of similar height and weight when they comply with eating any given diet because men have more lean body mass, less percent body fat, and therefore higher energy expenditure.",
"     </li>",
"     <li>",
"      Older subjects of either sex have a lower energy expenditure and therefore lose weight more slowly than younger subjects; metabolic rate declines by approximately 2 percent per decade (about 100",
"      <span class=\"nowrap\">",
"       kcal/decade)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The importance of genetic factors is illustrated by a study of identical male twin pairs who were overfed to induce weight gain [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/10\">",
"       10",
"      </a>",
"      ]. Twelve twin pairs were overfed by 1000",
"      <span class=\"nowrap\">",
"       kcal/day",
"      </span>",
"      for 84 of 100 days. The degree of weight gain at a constant dietary caloric increment varied widely among the twin pairs (from 4.3 to 13.3 kg), in fact, there was three times the variance for both weight and fat mass among the twin pairs when compared with that within the twin pairs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 22",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    is required to maintain a kilogram of body weight in a normal adult. Thus, the expected or calculated energy expenditure for a woman weighing 100 kg is approximately 2200",
"    <span class=\"nowrap\">",
"     kcal/day.",
"    </span>",
"    The variability of &plusmn;20 percent could give energy needs as high as 2620",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    or as low as 1860",
"    <span class=\"nowrap\">",
"     kcal/day.",
"    </span>",
"    An average deficit of 500",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    should result in an initial weight loss of approximately 0.5",
"    <span class=\"nowrap\">",
"     kg/week",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     lb/week).",
"    </span>",
"    However, after three to six months of weight loss, energy expenditure adaptations occur, which slow the bodyweight response to a given change in energy intake, thereby diminishing ongoing weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several methods of formally estimating energy expenditure; we suggest using the WHO criteria (",
"    <a class=\"graphic graphic_table graphicRef63308 \" href=\"UTD.htm?34/37/35419\">",
"     table 2",
"    </a>",
"    ). This method allows a direct estimate of resting metabolic rate (RMR) and calculation of daily energy requirement. The low activity level (1.3 x RMR) includes subjects who lead a sedentary life. The high activity level (1.7 x RMR) applies to those in jobs requiring manual labor or patients with regular daily physical exercise programs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Maintenance of weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for the overweight subject to understand that achieving and maintaining weight loss is made difficult by the reduction in energy expenditure that is induced by weight loss (",
"    <a class=\"graphic graphic_figure graphicRef63172 \" href=\"UTD.htm?22/60/23501\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/12\">",
"     12",
"    </a>",
"    ]. Weight loss maintenance is also difficult because of changes in the peripheral hormone signals that regulate appetite. Gastrointestinal peptides, such as ghrelin, which stimulates appetite, and gastric inhibitory polypeptide, which may promote energy storage, increase after diet-induced weight loss. Other circulating mediators that inhibit intake (eg, leptin, peptide YY, cholecystokinin, pancreatic polypeptide) decrease. These hormonal adaptations favoring weight gain persist for at least one year after diet-induced weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of therapy for obesity in adults\", section on 'Maintenance of weight loss'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis of obesity\", section on 'Ghrelin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TYPES OF DIETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general consensus is that excess intake of calories from any source, associated with a sedentary lifestyle, causes weight gain and obesity. The goal of dietary therapy, therefore, is to decrease energy intake from food. Conventional diets are defined as those below energy requirements but above 800",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/14\">",
"     14",
"    </a>",
"    ]. These diets fall into four groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Balanced low-calorie",
"      <span class=\"nowrap\">",
"       diets/portion-controlled",
"      </span>",
"      diets",
"     </li>",
"     <li>",
"      Low-fat diets",
"     </li>",
"     <li>",
"      Low-carbohydrate diets",
"     </li>",
"     <li>",
"      Mediterranean diet",
"     </li>",
"     <li>",
"      Fad diets (diets involving unusual combinations of foods or eating sequences)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Commercial weight loss programs and internet-based programs are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Balanced low-calorie diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planning a diet requires the selection of a caloric intake and then selection of foods to meet this intake. It is desirable to eat foods with adequate nutrients in addition to protein, carbohydrate, and essential fatty acids. Thus, weight-reducing diets should eliminate alcohol, sugar-containing beverages, and most highly concentrated sweets because they rarely contain adequate amounts of other nutrients besides energy.",
"   </p>",
"   <p>",
"    Breakdown of some protein is to be expected during weight loss. When weight increases as a result of overeating, approximately 75 percent of the extra energy is stored as fat and the remaining 25 percent as lean tissue. If the lean tissue contains 20 percent protein, then 5 percent of the extra weight gain would be protein. Thus, it should be anticipated that during weight loss, at least 5 percent of weight loss will be protein. A desirable feature of any calorie-restricted diet, however, is that it results in the lowest possible loss of protein, recognizing that this will not be less than 5 percent of the weight that is lost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Portion-controlled diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;One simple approach to providing a calorie-controlled diet is to use individually packaged foods, such as formula diet drinks using powdered or liquid formula diets, nutrition bars, frozen food, and pre-packaged meals that can be stored at room temperature as the main source of nutrients.",
"   </p>",
"   <p>",
"    Frozen low-calorie meals containing 250 to 350",
"    <span class=\"nowrap\">",
"     kcal/package",
"    </span>",
"    can be a convenient and nutritious way to do this. We have often recommended the use of formula diets or breakfast bars for breakfast, formula diets or a frozen lunch entree for lunch, and a frozen calorie-controlled entree with additional vegetables for dinner. In this way, it is possible to obtain a calorie-controlled 1000 to 1500 kcal per day diet. In one four-year study this approach resulted in early initial weight loss, which then was maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/15\">",
"     15",
"    </a>",
"    ]. I do not recommend the use of formula diets alone because they do not provide adequate nutritional variety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Low-fat diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-fat diets are another standard strategy to help patients lose weight, and almost all dietary guidelines recommend a reduction in the daily intake of fat to 30 percent of energy intake or less [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a meta-analysis of trials comparing low-fat diets (typically 20 to 25 percent of energy from fats) with a control group consuming a usual diet or a medium fat diet (usually 35 to 40 percent of energy), there was greater weight loss (approximately 3 kg) with low-fat compared with moderate fat diets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, one report noted that people who successfully keep their weight reduced adopt three strategies, one of which is eating a lower fat diet [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link\">",
"     \"Dietary fat\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology and natural history of obesity\", section on 'Dietary habits'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A low-fat dietary pattern with healthy carbohydrates is not associated with weight gain. This was illustrated by the Women's Health Initiative Dietary Modification Trial of 48,835 postmenopausal women over age 50 years who were randomly assigned to a dietary intervention that included group and individual sessions to promote a decrease in fat intake and increases in fruit, vegetable, and grain consumption (healthy carbohydrates), but did not include weight loss or caloric restriction goals, or a control group which received only dietary educational materials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/20\">",
"     20",
"    </a>",
"    ]. After an average of 7.5 years of follow-up, the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women in the intervention group lost weight in the first year (mean of 2.2 kg) and maintained lower weight than the control women at 7.5 years (difference of 1.9 kg at one year, and 0.4 kg at 7.5 years).",
"     </li>",
"     <li>",
"      No tendency toward weight gain was seen in the intervention group overall, or when stratified by age, ethnicity, or body mass index.",
"     </li>",
"     <li>",
"      Weight loss was related to the level of fat intake and was greatest in women who decreased their percentage of energy from fat the most. A similar, but lesser trend was seen with increased vegetable and fruit intake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A low-fat diet can be implemented in two ways. First, the dietitian can provide the subject with specific menu plans that emphasize the use of reduced fat foods. As one guideline, if a food \"melts\" in your mouth, it probably has fat in it. Second, subjects can be instructed in counting fat grams as an alternative to counting calories. Fat has 9.4",
"    <span class=\"nowrap\">",
"     kcal/g.",
"    </span>",
"    It is thus very easy to calculate the number of grams of fat a subject can eat for any given level of energy intake.",
"   </p>",
"   <p>",
"    Many experts recommend keeping calories from fat to below 30 percent of total calories. In practical terms, this means eating about 33 g of fat for each 1000 calories in the diet. For simplicity, I use 30 g of fat or less for each 1000 kcal. For a 1500-calorie diet, this would mean about 45 g or less of fat, which can be counted using the nutrition information labels on food packages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Low-carbohydrate diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proponents of low-carbohydrate diets have argued that the increasing obesity epidemic may be in part due to low-fat, high-carbohydrate diets. But this may be dependent upon the type of carbohydrates that are eaten, such as energy dense snacks and sugar or high fructose containing beverages.",
"   </p>",
"   <p>",
"    The carbohydrate content of the diet is an important determinant of short-term (less than two weeks) weight loss. Low (60 to 130 grams of carbohydrates) and very low-carbohydrate diets (0 to &lt;60 grams) have been popular for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/14\">",
"     14",
"    </a>",
"    ]. Restriction of carbohydrates leads to glycogen mobilization and, if carbohydrate intake is less than 50",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    ketosis will develop. Rapid weight loss occurs, primarily due to glycogen breakdown and fluid loss rather than fat loss.",
"   </p>",
"   <p>",
"    Low and very low-carbohydrate diets are more effective for short-term weight loss than low-fat diets, although probably not for long-term weight loss. A meta-analysis of five trials found that the difference in weight loss at six months, favoring the low carbohydrate over low fat diet, was not sustained at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Comparison trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Low-carbohydrate diets may have some other beneficial effects with regard to risk of developing type 2 diabetes mellitus, coronary heart disease, and some cancers, particularly if attention is paid to the type as well as the quantity of carbohydrate. A low-carbohydrate diet can be implemented in two ways, either by reducing the total amount of carbohydrate or by consuming foods with a lower glycemic index or glycemic load (",
"    <a class=\"graphic graphic_table graphicRef56170 \" href=\"UTD.htm?15/40/16012\">",
"     table 3",
"    </a>",
"    ). Glycemic index and load are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link&amp;anchor=H3#H3\">",
"     \"Dietary carbohydrates\", section on 'Glycemic index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a low-carbohydrate diet is chosen, healthy choices for fat (mono- and polyunsaturated fats) and protein (fish, nuts, legumes, and poultry) should be encouraged because of the association between saturated fat intake and risk of coronary heart disease. During 26 years of follow-up of women in the Nurses' Health Study and 20 years of follow-up of men in the Health Professionals&rsquo; Follow-up Study, low carbohydrate diets in the highest versus lowest decile for vegetable proteins and fat were associated with lower all-cause mortality (HR 0.80, 95% CI 0.75-0.85) and cardiovascular mortality (HR 0.77, 95% CI 0.68-0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast, low carbohydrate diets in the highest versus lowest decile for animal protein and fat were associated with higher all-cause (HR 1.23, 95% CI 1.11-1.37) and cardiovascular (HR 1.14, 95% CI 1.01-1.29) mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link\">",
"     \"Dietary fat\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\", section on 'Healthy diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     High protein diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some popular books recommend high protein diets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/23\">",
"     23",
"    </a>",
"    ]. In one trial, low-fat diets with 12 percent and 25 percent protein content were compared. Weight loss over six months was greater with the higher protein diet (9 versus 5 kg), but the difference was no longer significant at 12 and 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher protein diets may improve weight maintenance, as illustrated by the results of a study of 60 subjects randomly assigned to a low fat, high protein versus low-fat, high-carbohydrate diet after completing a four week very low calorie diet [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/25\">",
"     25",
"    </a>",
"    ]. Among the subjects who completed the three-month study (n = 48), the high protein diet group had significantly better weight maintenance (between group difference of 2.3 kg).",
"   </p>",
"   <p>",
"    High dietary protein intake, due to its acid-producing load, increases urinary calcium excretion (with potential risk for bone loss and calcium stone formation) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/26\">",
"     26",
"    </a>",
"    ]. Urinary calcium excretion does appear to increase when dietary intake of protein increases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/26-28\">",
"     26-28",
"    </a>",
"    ], and this could pose a long-term risk for nephrolithiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H15#H15\">",
"     \"Risk factors for calcium stones in adults\", section on 'Dietary risk factors'",
"    </a>",
"    .) However, two small randomized trials that looked at bone metabolism found evidence that increased dietary protein may decrease bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. One of the trials found that increased intestinal absorption of calcium was primarily responsible for the increased urinary excretion of calcium and that the excreted calcium was not coming from bone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mediterranean diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term Mediterranean diet refers to a dietary pattern that is common in olive-growing areas of the Mediterranean area. Although there is some variation in Mediterranean diets, there are some common components that include a high level of monounsaturated fat relative to saturated; moderate consumption of alcohol, mainly as wine; a high consumption of vegetables, fruits, legumes, and grains; a moderate consumption of milk and dairy products, mostly in the form of cheese; and a relatively low intake of meat and meat products.",
"   </p>",
"   <p>",
"    A meta-analysis of 12 studies involving eight cohorts found that a Mediterranean diet was associated with improved health status and reductions in overall mortality, cardiovascular mortality, cancer mortality, and incidence of Parkinson's disease and Alzheimer's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link&amp;anchor=H24#H24\">",
"     \"Healthy diet in adults\", section on 'Mediterranean diet'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Very low-calorie diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diets with energy levels between 200 and 800",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    are called \"very low-calorie diets,\" while those below 200",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    can be termed starvation diets. The basis for these diets was the notion that the lower the calorie intake the more rapid the weight loss, because the energy withdrawn from body fat stores is a function of the energy deficit. Starvation is the ultimate very low-calorie diet and results in the most rapid weight loss. Although once popular, starvation diets are now rarely used for treatment of obesity.",
"   </p>",
"   <p>",
"    Very low-calorie diets have not been shown to be superior to conventional diets for long-term weight loss. In a meta-analysis of six trials comparing very low-calorie diets with conventional low-calorie diets, short-term weight loss was greater with very low-calorie diets (16.1 versus 9.7 versus percent of initial weight), but there was no difference in long-term weight loss (6.3 versus 5.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with all diets, very low-calorie diets initially result in substantial protein loss that diminishes with time. Other expected effects include reduction in blood pressure and improvement in hyperglycemia in diabetic patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects adhering to very low-calorie diets usually have a fall in blood pressure, especially during the first week. Antihypertensive drugs, especially calcium channel blockers and diuretics, should usually be discontinued when a very low calorie diet is begun unless moderate to severe hypertension is present.",
"     </li>",
"     <li>",
"      Most diabetic patients eating very low-calorie diets have marked improvement in hyperglycemia. Blood glucose concentrations fall within the first one to two weeks, and remain lower as long as the diet is continued. Those patients taking less than 50 units of insulin or an oral hypoglycemic drug will usually be able to discontinue therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The side effects of very low-calorie diets include hair loss, thinning of the skin, and coldness. These diets are contraindicated for lactating and pregnant women, and in children who require protein for linear growth. As with all diets, there is increased cholesterol mobilization from peripheral fat stores, thus increasing the risk of gallstones.",
"   </p>",
"   <p>",
"    Very low-calorie diets should be reserved for subjects who require rapid weight loss for a specific purpose, such as surgery. The weight regain when the diet is stopped is often rapid, and it is better to take a more sustainable approach than to use a method that cannot be sustained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Comparison trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of specific dietary composition on weight change remains uncertain. When energy from dietary carbohydrates decreases, energy from fat sources tends to increase. The reverse is also true; when energy from dietary fats decreases, energy from carbohydrate sources tends to increase. The debate has mainly centered on whether low-fat or low-carbohydrate diets can better induce weight loss and sustain it over the long-term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Weight loss diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial trials evaluating the effect of type of diet (predominantly low-carbohydrate versus low-fat) on weight loss and other outcomes showed that weight loss at six months was approximately 4 kg greater in the very low-carbohydrate group than in the low-fat group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Trials lasting for one year, however, did not find a significant difference in weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/33,35,36\">",
"     33,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses of trials comparing low-fat and low-carbohydrate diets found that the difference in weight loss at six months (weighted mean difference 3 to 4 kg), favoring the low carbohydrate over low fat diet, was not sustained at 12 months (weighted mean difference 1 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/21,37\">",
"     21,37",
"    </a>",
"    ]. In one study, this convergence was mainly due to regain of weight in the low-carbohydrate group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/33\">",
"     33",
"    </a>",
"    ]; in another, the convergence was due to ongoing weight loss in the low-fat group (",
"    <a class=\"graphic graphic_figure graphicRef65417 \" href=\"UTD.htm?25/17/25885\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of these initial comparison trials of different dietary regimens had important limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/21\">",
"     21",
"    </a>",
"    ]. These included high dropout rates (21 to 48 percent), suboptimal dietary compliance, and limited long-term follow-up.",
"   </p>",
"   <p>",
"    Subsequent trials are larger, of longer duration (lasting one to two years), and have conflicting results with regard to the impact of macronutrient composition on weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. In contrast, all trials found that dietary adherence is an important determinant of weight loss, independent of macronutrient composition. The following observations illustrate the range of findings in these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 322 moderately obese subjects (86 percent men) were randomly assigned to a low-fat (restricted calorie), Mediterranean (moderate-fat, restricted calorie, rich in vegetables, low in red meat), or low-carbohydrate (non-restricted-calorie) diet for two years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/38\">",
"       38",
"      </a>",
"      ]. Adherence rates were higher than those reported in previous trials (95.4 and 84.6 percent at one and two years, respectively). Weight loss was greater with the Mediterranean and low-carbohydrate diets than the low-fat diet (mean weight loss 4.4, 4.7, and 2.9 kg, respectively).",
"      <br/>",
"      <br/>",
"      The most favorable effect on lipids (increased HDL and decreased triglycerides and ratio of total cholesterol to HDL) was seen in the low-carbohydrate group. Among subjects with type 2 diabetes, the greatest improvement in glycemic control occurred with the Mediterranean diet. Among all groups, weight loss was greater for those who completed the two year study than for those who withdrew.",
"     </li>",
"     <li>",
"      Another randomized trial compared four different diets in 311 overweight and obese premenopausal women: very low-carbohydrate (Atkins); macronutrient balance controlling glycemic load (Zone); general calorie restriction, low-fat (LEARN); and very low-fat (Ornish) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/39\">",
"       39",
"      </a>",
"      ]. In the intention-to-treat analysis at one year, mean weight loss was greater in the Atkins diet group compared with the other groups (4.7, 1.6, 2.2, and 2.6 kg, respectively). Pairwise comparisons showed a significant difference only for Atkins versus Zone.",
"      <br/>",
"      <br/>",
"      The most favorable effect on triglycerides and HDL-C was seen in the Atkins group. Dietary adherence rates (77 to 88 percent) were similar among the groups and better than in previous trials. Within each group, adherence was significantly associated with weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the largest trial to date, 811 overweight and obese adults were randomly assigned to one of four diets based upon macronutrient content: low or high fat (20 to 40 percent), which provided carbohydrate at 35, 45, 55, or 65 percent, and high or average protein (15 to 25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/40\">",
"       40",
"      </a>",
"      ]. After six months, mean weight loss in each group was 6 kg. By two years, mean weight loss was 3 to 4 kg, and weight losses remained similar in all groups. Many participants had trouble attaining target levels of macronutrients. Subjects who attended the greatest number of group sessions (most adherent) lost the most weight.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, any diet that is adhered to will produce modest weight loss, but adherence rates are low with most diets. Although a low-carbohydrate diet may be associated with greater short-term weight loss, superior weight loss in the long-term has not been established. The optimal mix of macronutrients likely depends upon individual factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/43\">",
"     43",
"    </a>",
"    ]. A principal determinant of weight loss appears to be the degree of adherence to the diet, irrespective of the particular macronutrient composition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/36,39,40,42,44,45\">",
"     36,39,40,42,44,45",
"    </a>",
"    ]. Thus, we suggest choosing a macronutrient mix based upon patient preferences, which may improve long-term adherence.",
"   </p>",
"   <p>",
"    Behavioral modification to improve dietary compliance with any type of diet may have the greatest impact on long-term weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observed effects on blood lipids were similar for trials comparing low fat and very low carbohydrate diets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/21,32-35,46\">",
"     21,32-35,46",
"    </a>",
"    ]; the",
"    <span class=\"nowrap\">",
"     low-carbohydrate/high-fat",
"    </span>",
"    diets caused slight increases in HDL, and greater decreases in fasting triglycerides. At 12 to 24 months, however, the favorable effects on HDL persisted [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/33,35,36,41\">",
"     33,35,36,41",
"    </a>",
"    ], while triglyceride levels were either reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/33,35\">",
"     33,35",
"    </a>",
"    ] or returned to baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analyses of trials comparing low-carbohydrate and low-fat diet groups, LDL levels were increased in the low-carbohydrate group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/21,37\">",
"     21,37",
"    </a>",
"    ]. There was no clear benefit of either low-fat or low-carbohydrate diet on cardiovascular risks. Favorable changes in HDL cholesterol and triglycerides should be weighed against potential unfavorable changes in LDL cholesterol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very low-carbohydrate diets may be associated with more frequent side effects than low-fat diets. In one of the trials noted above, a number of symptoms occurred significantly more frequently in the low-carbohydrate compared to the low-fat diet group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/32\">",
"     32",
"    </a>",
"    ]. These included constipation (68 versus 35 percent), headache (60 versus 40 percent), halitosis (38 versus 8 percent), muscle cramps (35 versus 7 percent), diarrhea (23 versus 7 percent), general weakness (25 versus 8 percent), and rash (13 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/32\">",
"     32",
"    </a>",
"    ]. Despite the higher rate of symptoms, dropout rates in clinical trials have been similar for low-carbohydrate and low-fat diets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have raised the concern about ketosis that occurs with very low-carbohydrate diets. There is one case report of an obese patient who presented in severe ketoacidosis, having lost 9 kg in one month on the Atkins diet, with intake restricted to meat, cheese, and salads [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/47\">",
"     47",
"    </a>",
"    ]. Aside from her diet and possible mild dehydration due to gastroenteritis, no other cause for her ketoacidosis was identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19970412\">",
"    <span class=\"h3\">",
"     Weight maintenance diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many individuals have success losing weight with diet, most subsequently regain much or all of the lost weight. Maintaining weight loss is made difficult by the reduction in energy expenditure that is induced by weight loss. In addition, long-term adherence to restrictive diets is difficult. Exercise and behavioral interventions may help individuals maintain weight loss. These strategies are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link&amp;anchor=H10#H10\">",
"     \"Role of physical activity and exercise in obese adults\", section on 'Maintenance of weight loss'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link&amp;anchor=H20#H20\">",
"     \"Behavioral strategies in the treatment of obesity\", section on 'Maintenance of weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little consensus on the optimal mix of macronutrients to maintain weight loss. The satiating effects of high protein, low glycemic index diets have generated interest in manipulating protein composition and glycemic index in weight maintenance diets. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'High protein diets'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link&amp;anchor=H12#H12\">",
"     \"Dietary carbohydrates\", section on 'Effect of glycemic index/glycemic load'",
"    </a>",
"    .) In a multicenter trial of five ad libitum diets to prevent weight regain over 26 weeks, 773 adults who had successfully lost 8 percent of their body weight on a low calorie diet (800 to 1000",
"    <span class=\"nowrap\">",
"     kcal/day),",
"    </span>",
"    were randomly assigned in a two-by-two factorial design to a high or low-protein (25 versus 13 percent of total calories), high or low-glycemic index, or to a control diet (moderate protein content) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/48\">",
"     48",
"    </a>",
"    ]. All diets had a moderate fat content (25 to 30 percent). The achieved protein content was 5 percentage points higher in the high versus low protein groups, and the mean glycemic index was five units lower in the low-glycemic versus high-glycemic index groups.",
"   </p>",
"   <p>",
"    In the intention-to-treat analysis, weight regain during the trial was modestly but significantly greater in the low versus high-protein groups (mean difference 0.93 kg) and in the high versus low-glycemic index groups (mean difference 0.95 kg). Only subjects in the high-protein, low-glycemic index diet group continued to lose weight (mean change -0.38 kg). The trial was limited by the moderate dropout rate (29 percent) and short-term follow-up (six months).",
"   </p>",
"   <p>",
"    In a small four-week crossover trial in 21 obese and overweight young adults who had achieved a 10 to 15 percent weight loss, a low fat diet resulted in decreases in resting and total energy expenditure compared with low glycemic-index and very low-carbohydrate diets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/49\">",
"     49",
"    </a>",
"    ]. Due to the short-term follow-up in the study, the clinical implications for maintaining weight loss are unknown.",
"   </p>",
"   <p>",
"    Whether the macronutrient composition of a diet, independent of total calorie intake, has any effect on long-term weight maintenance is unknown. As discussed above, long-term adherence to a weight maintaining diet is probably the most important determinant of success, and therefore the optimal weight maintaining diet will depend upon preference and individual factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Role of dietary counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary counseling may produce modest, short-term weight losses. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link&amp;anchor=H5#H5\">",
"     \"Behavioral strategies in the treatment of obesity\", section on 'Elements of behavioral strategies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link&amp;anchor=H17#H17\">",
"     \"Behavioral strategies in the treatment of obesity\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prolonged caloric restriction and longevity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/52\">",
"     52",
"    </a>",
"    ], studies, prolonged caloric restriction improved longevity in rodents and non-human primates, but the impact of calorie restriction on longevity in humans is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/53\">",
"     53",
"    </a>",
"    ]. It is hypothesized that the antiaging effects of caloric restriction are due to reduced energy expenditure resulting in a reduction in production of reactive oxygen species (and therefore a reduction in oxidative damage). In addition, other metabolic effects associated with caloric restriction, such as improved insulin sensitivity, might also have an antiaging effect. In one trial of 48 sedentary, overweight men and women, six months of caloric restriction, with or without exercise, resulted in significant weight loss as expected [",
"    <a class=\"abstract\" href=\"UTD.htm?8/9/8345/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, calorie restriction-mediated reductions in fasting insulin concentrations, core body temperature, serum T3 levels, and oxidative damage to DNA (as reflected by a reduction in DNA fragmentation) were seen, suggesting a possible antiaging effect of the prolonged caloric restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"       \"Patient information: Diet and health (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       \"Patient information: Weight loss treatments (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"       \"Patient information: Diet and health (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"       \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial weight loss goal of 5 to 7 percent of body weight is realistic for most individuals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many types of diets produce modest weight loss. Options include balanced low-calorie, low-fat low-calorie, moderate-fat low calorie, low-carbohydrate diets, and the Mediterranean diet. Dietary adherence is an important predictor of weight loss, irrespective of the type of diet. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Types of diets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest tailoring a diet that reduces energy intake below energy expenditure to individual patient preferences, rather than focusing on the macronutrient composition of the diet (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Comparison trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a low-carbohydrate diet is chosen, healthy choices for fat (mono and polyunsaturated) and protein (fish, nuts, legumes, and poultry) should be encouraged. If a low-fat diet is chosen, the decrease in fat should be accompanied by increases in healthy carbohydrates (fruits, vegetables, whole grains).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/1\">",
"      Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65:79.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health, National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication Number 00-4084, October 2000. file://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf (Accessed on December 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/3\">",
"      Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005; 29:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/4\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/5\">",
"      Heymsfield SB, Harp JB, Reitman ML, et al. Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective. Am J Clin Nutr 2007; 85:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/6\">",
"      Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011; 378:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/7\">",
"      Trabulsi J, Schoeller DA. Evaluation of dietary assessment instruments against doubly labeled water, a biomarker of habitual energy intake. Am J Physiol Endocrinol Metab 2001; 281:E891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/8\">",
"      Tooze JA, Schoeller DA, Subar AF, et al. Total daily energy expenditure among middle-aged men and women: the OPEN Study. Am J Clin Nutr 2007; 86:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/9\">",
"      Roberts SB, Rosenberg I. Nutrition and aging: changes in the regulation of energy metabolism with aging. Physiol Rev 2006; 86:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/10\">",
"      Bouchard C, Tremblay A, Despr&eacute;s JP, et al. The response to long-term overfeeding in identical twins. N Engl J Med 1990; 322:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/11\">",
"      Lin PH, Proschan MA, Bray GA, et al. Estimation of energy requirements in a controlled feeding trial. Am J Clin Nutr 2003; 77:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/12\">",
"      Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr 2008; 88:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/13\">",
"      Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/14\">",
"      Freedman MR, King J, Kennedy E. Popular diets: a scientific review. Obes Res 2001; 9 Suppl 1:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/15\">",
"      Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000; 8:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/16\">",
"      Astrup A, Hill JO, Saris WH. Dietary fat: at the heart of the matter. Science 2001; 293:801.",
"     </a>",
"    </li>",
"    <li>",
"     Medline Plus: Diets file://www.nlm.nih.gov/medlineplus/diets.html#cat1 (Accessed on July 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/18\">",
"      Phelan S, Liu T, Gorin A, et al. What distinguishes weight-loss maintainers from the treatment-seeking obese? Analysis of environmental, behavioral, and psychosocial variables in diverse populations. Ann Behav Med 2009; 38:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/19\">",
"      Foreyt JP, Goodrick GK. Factors common to successful therapy for the obese patient. Med Sci Sports Exerc 1991; 23:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/20\">",
"      Howard BV, Manson JE, Stefanick ML, et al. Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA 2006; 295:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/21\">",
"      Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/22\">",
"      Fung TT, van Dam RM, Hankinson SE, et al. Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies. Ann Intern Med 2010; 153:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/23\">",
"      Paddon-Jones D, Westman E, Mattes RD, et al. Protein, weight management, and satiety. Am J Clin Nutr 2008; 87:1558S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/24\">",
"      Due A, Toubro S, Skov AR, Astrup A. Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes Relat Metab Disord 2004; 28:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/25\">",
"      Claessens M, van Baak MA, Monsheimer S, Saris WH. The effect of a low-fat, high-protein or high-carbohydrate ad libitum diet on weight loss maintenance and metabolic risk factors. Int J Obes (Lond) 2009; 33:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/26\">",
"      Ince BA, Anderson EJ, Neer RM. Lowering dietary protein to U.S. Recommended dietary allowance levels reduces urinary calcium excretion and bone resorption in young women. J Clin Endocrinol Metab 2004; 89:3801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/27\">",
"      Dawson-Hughes B, Harris SS, Rasmussen H, et al. Effect of dietary protein supplements on calcium excretion in healthy older men and women. J Clin Endocrinol Metab 2004; 89:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/28\">",
"      Kerstetter JE, O'Brien KO, Caseria DM, et al. The impact of dietary protein on calcium absorption and kinetic measures of bone turnover in women. J Clin Endocrinol Metab 2005; 90:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/29\">",
"      Sofi F, Cesari F, Abbate R, et al. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008; 337:a1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/30\">",
"      Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006; 14:1283.",
"     </a>",
"    </li>",
"    <li>",
"     Management of obesity by severe caloric restriction, Blackburn GL, Bray GA (Eds), PSG Publishing Co., Littleton, MA 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/32\">",
"      Yancy WS Jr, Olsen MK, Guyton JR, et al. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004; 140:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/33\">",
"      Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003; 348:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/34\">",
"      Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/35\">",
"      Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004; 140:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/36\">",
"      Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/37\">",
"      Hession M, Rolland C, Kulkarni U, et al. Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. Obes Rev 2009; 10:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/38\">",
"      Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008; 359:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/39\">",
"      Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 2007; 297:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/40\">",
"      Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/41\">",
"      Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med 2010; 153:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/42\">",
"      Alhassan S, Kim S, Bersamin A, et al. Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study. Int J Obes (Lond) 2008; 32:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/43\">",
"      Corella D, Peloso G, Arnett DK, et al. APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations. Arch Intern Med 2009; 169:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/44\">",
"      Wadden TA, Neiberg RH, Wing RR, et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring) 2011; 19:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/45\">",
"      Del Corral P, Chandler-Laney PC, Casazza K, et al. Effect of dietary adherence with or without exercise on weight loss: a mechanistic approach to a global problem. J Clin Endocrinol Metab 2009; 94:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/46\">",
"      Ebbeling CB, Leidig MM, Feldman HA, et al. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA 2007; 297:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/47\">",
"      Chen TY, Smith W, Rosenstock JL, Lessnau KD. A life-threatening complication of Atkins diet. Lancet 2006; 367:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/48\">",
"      Larsen TM, Dalskov SM, van Baak M, et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med 2010; 363:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/49\">",
"      Ebbeling CB, Swain JF, Feldman HA, et al. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA 2012; 307:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/50\">",
"      Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009; 325:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/51\">",
"      Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr 2003; 78:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/52\">",
"      Mattison JA, Roth GS, Beasley TM, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012; 489:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/53\">",
"      Redman LM, Ravussin E. Caloric restriction in humans: impact on physiological, psychological, and behavioral outcomes. Antioxid Redox Signal 2011; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/9/8345/abstract/54\">",
"      Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 2006; 295:1539.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5375 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-9E6818F356-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8345=[""].join("\n");
var outline_f8_9_8345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIETARY ENERGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rate of weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Maintenance of weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TYPES OF DIETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Balanced low-calorie diets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Portion-controlled diets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Low-fat diets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Low-carbohydrate diets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      High protein diets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mediterranean diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Very low-calorie diets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Comparison trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Weight loss diets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19970412\">",
"      - Weight maintenance diets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Role of dietary counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prolonged caloric restriction and longevity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/5375\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5375|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/26/15778\" title=\"figure 1\">",
"      Obesity risk algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/60/23501\" title=\"figure 2\">",
"      Energy expenditure and weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/17/25885\" title=\"figure 3\">",
"      Low-carb versus conventional diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5375|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/13/20700\" title=\"table 1\">",
"      BMI waist circumference risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/37/35419\" title=\"table 2\">",
"      Estimating energy expenditure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/40/16012\" title=\"table 3\">",
"      Glycemic index of foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=related_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=related_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_9_8346="Moderate FGS Light";
var content_f8_9_8346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moderate FGS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in focal segmental glomerulosclerosis shows a moderately large segmental area of sclerosis with capillary collapse on the upper left side of the glomerular tuft; the lower right segment is relatively normal. Focal deposition of hyaline material (arrow) is also seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8346=[""].join("\n");
var outline_f8_9_8346=null;
var title_f8_9_8347="Retinoids for photoaging";
var content_f8_9_8347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prescription topical retinoids for treatment of photoaging",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Topical retinoid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage forms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tretinoin",
"       </td>",
"       <td>",
"        <p>",
"         Avita (0.025% cream and gel)",
"        </p>",
"        <p>",
"         Atralin (0.05% gel)",
"        </p>",
"        <p>",
"         Refissa (0.05% cream)",
"        </p>",
"        <p>",
"         Renova (0.02% cream)",
"        </p>",
"        <p>",
"         Retin-A (0.025%, 0.05%, 0.1% cream; 0.01%, 0.025% gel)",
"        </p>",
"        <p>",
"         Retin-A Micro (0.04% and 0.1% microsphere gel)",
"        </p>",
"        <p>",
"         Tretin-X (0.025%, 0.05%, 0.1% cream; 0.01% , 0.025% gel)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Tazarotene",
"       </td>",
"       <td>",
"        <p>",
"         Tazorac (0.05%, 0.1% gel and cream)",
"        </p>",
"        <p>",
"         Avage (0.1% cream)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Chien A, Voorhees JJ, King S. Topical retinoids. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA (Ed), McGraw-Hill, 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8347=[""].join("\n");
var outline_f8_9_8347=null;
var title_f8_9_8348="ESC risk stratification WPW";
var content_f8_9_8348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for risk stratification for sudden cardiac death proposed by the European Society of Cardiology (ESC): Wolff-Parkinson-White syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short (&lt;250 ms) RR interval during atrial fibrillation",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short (&lt;270 ms) anterograde refractory period of the accessory pathway",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple accessory pathways",
"       </td>",
"       <td>",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of pre-excitation ajmaline or procainamide test (lower risk)",
"       </td>",
"       <td>",
"        Class IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syncope",
"       </td>",
"       <td>",
"        Class III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Recommendations from the European Society of Cardiology for additional risk stratification for sudden cardiac death in patients with specific clinical findings in the setting of Wolff-Parkinson-White syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Eur Heart J 2001; 22:1374.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8348=[""].join("\n");
var outline_f8_9_8348=null;
var title_f8_9_8349="Delayed organophos agents";
var content_f8_9_8349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Agents associated with organophosphorous induced delayed neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 160px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8349=[""].join("\n");
var outline_f8_9_8349=null;
var title_f8_9_8350="ACLS AF rate rhythm control I";
var content_f8_9_8350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68352%7ECARD%2F80760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68352%7ECARD%2F80760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the control of rate and rhythm in atrial fibrillation/flutter-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Cardiac function preserved",
"      </td>",
"      <td class=\"subtitle1\">",
"       Impaired cardiac function EF &lt;40 percent or HF",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration &lt;48 hours",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration &gt;48 hours or unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Normal cardiac function",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Note: If AF &gt;48 hours duration, use agents to convert rhythm with extreme caution in patients not receiving adequate anticoagulation because of possible embolic complications.",
"       </p>",
"       <p>",
"        <strong>",
"         Use only 1 of the following agents:",
"        </strong>",
"       </p>",
"       <p>",
"        Calcium channel blockers (Class 1)",
"       </p>",
"       <p>",
"        Beta-blockers (Class 1)",
"       </p>",
"       <p>",
"        Additional drugs are Class lIb recommendations",
"       </p>",
"      </td>",
"      <td>",
"       (Does not apply)",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Consider:",
"        </strong>",
"        DC cardioversion",
"       </p>",
"       <p>",
"        <strong>",
"         Use only 1 of the following agents:",
"        </strong>",
"       </p>",
"       <p>",
"        Amiodarone (Class Ila)",
"       </p>",
"       <p>",
"        Ibutilide (Class Ila)",
"       </p>",
"       <p>",
"        Flecainide (Class Ila)",
"       </p>",
"       <p>",
"        Propafenone (Class Ila)",
"       </p>",
"       <p>",
"        Procainamide (Class Ila)",
"       </p>",
"       <p>",
"        Other drugs are Class IIb recommendations",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         NO DC cardioversion!",
"        </strong>",
"       </p>",
"       <p>",
"        Note: Conversion of AF to NSR with drugs or shock may cause embolization of atrial thrombi unless patient has adequate anticoagulation.",
"       </p>",
"       <p>",
"        Use antiarrhythmic agents with extreme caution if AF &gt;48 hours duration.",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Delayed cardioversion anticoagulation x3 weeks at proper levels",
"        </strong>",
"       </p>",
"       <p>",
"        Cardioversion, then Anticoagulation x4 weeks more",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Early cardioversion",
"        </strong>",
"       </p>",
"       <p>",
"        Begin IV heparin at once",
"       </p>",
"       <p>",
"        TEE to exclude atrial clot",
"       </p>",
"       <p>",
"        <strong>",
"         THEN",
"        </strong>",
"       </p>",
"       <p>",
"        Cardioversion within 24 hours",
"       </p>",
"       <p>",
"        <strong>",
"         THEN",
"        </strong>",
"       </p>",
"       <p>",
"        Anticoagulation x4 more weeks",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Impaired cardiac function (EF &lt;40 percent or HF)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       (Does not apply)",
"      </td>",
"      <td>",
"       Note: If AF &gt;48 hours duration, use agents to convert rhythm with extreme caution in patients not receiving adequate anticoagulation because of possible embolic complications.",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Consider:",
"        </strong>",
"       </p>",
"       <p>",
"        DC cardioversion",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"       <p>",
"        Amiodarone (Class Ilb)",
"       </p>",
"       <p>",
"        <strong>",
"         Use only 1 of the following agents:",
"        </strong>",
"       </p>",
"       <p>",
"        Digoxin (Class lIb)",
"       </p>",
"       <p>",
"        Diltiazem (Class IIb)",
"       </p>",
"       <p>",
"        Amiodarone (Class Ilb)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Anticoagulation",
"       </p>",
"       <p>",
"        DC cardioversion",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: may have proarrhythmic potential. The classes listed represent the AHA Class of Recommendation and not the Vaughn-Williams classification of antiarrhythmics.",
"    <div class=\"footnotes\">",
"     WPW: Wolff-Parkinson-White syndrome; AF: atrial fibrillation; NSR: normal sinus rhythm; TEE: transesophageal echocardlogram; EF: ejection fraction.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: Circulation 2000 I-158.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the control of rate and rhythm in atrial fibrillation/flutter-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Control rate",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Convert rhythm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Cardiac function preservation",
"       </td>",
"       <td class=\"subtitle2\">",
"        Impaired cardiac function EF &lt;40 percent of HF",
"       </td>",
"       <td class=\"subtitle2\">",
"        Duration &lt;48 hours",
"       </td>",
"       <td class=\"subtitle2\">",
"        Duration &gt;48 hours or unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        WPW",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Note: IF AF &gt;48 hours duration, use agents to convert rhythm with extreme caution in patients not receiving adequate anticoagulation because of possible embolic complications.",
"        </p>",
"        <p>",
"         DC cardioversion",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Primary anti- arrhythmic agents-",
"        </p>",
"        <p>",
"         Use only 1 of the following agents:",
"        </p>",
"        <p>",
"         Amiodarone",
"        </p>",
"        <p>",
"         Flecainide (Class IIb)",
"        </p>",
"        <p>",
"         Procainamide (Class IIb)",
"        </p>",
"        <p>",
"         Propafenone (Class IIb)",
"        </p>",
"        <p>",
"         Sotalol (Class IIb)",
"        </p>",
"        <p>",
"         <strong>",
"          Class III (can be harmful)",
"         </strong>",
"        </p>",
"        <p>",
"         Adenosine",
"        </p>",
"        <p>",
"         Beta-blockers",
"        </p>",
"        <p>",
"         Calcium blockers",
"        </p>",
"        <p>",
"         Digoxin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Note: If AF &gt;48 hours duration, use agents to convert rhythm with extreme caution in patients not receiving adequate anticoagulation because of possible embolic complications.",
"        </p>",
"        <p>",
"         DC cardioversion",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Amiodarone (Class IIb)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         DC cardioversion",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Primary anti-arrhythmic agents",
"        </p>",
"        <p>",
"         Use only 1 of the following agents:",
"        </p>",
"        <p>",
"         Amiodarone (Class IIb)",
"        </p>",
"        <p>",
"         Flecainide (Class llb)",
"        </p>",
"        <p>",
"         Procainamide (Class Ilb)",
"        </p>",
"        <p>",
"         Propafenone (Class lIb)",
"        </p>",
"        <p>",
"         Sotalol",
"        </p>",
"        <p>",
"         <strong>",
"          Class III (can be harmful)",
"         </strong>",
"        </p>",
"        <p>",
"         Adenosine",
"        </p>",
"        <p>",
"         Beta-blockers",
"        </p>",
"        <p>",
"         Calcium blockers",
"        </p>",
"        <p>",
"         Digoxin",
"        </p>",
"       </td>",
"       <td>",
"        Anticoagulation followed by DC cardioversion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: Occasionally 2 of the named antiarrhythmic agents may be used, but use of these agents in combination may have proarrhythmic potential. The classes listed represent the AHA Class of Recommendation and not the Vaughn-Williams classification of antiarrhythmics.",
"    <div class=\"footnotes\">",
"     WPW: Wolff-Parkinson-White syndrome; AF: atrial fibrillation; NSR: normal sinus rhythm; EF: ejection fraction; HF: heart failure.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: Circulation 2000 I-158.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8350=[""].join("\n");
var outline_f8_9_8350=null;
var title_f8_9_8351="shawl sign";
var content_f8_9_8351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The shawl sign in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H. Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_9_8351=[""].join("\n");
var outline_f8_9_8351=null;
